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ABSTRACT OF DISSERTATION

ROLE OF SCAVENGER RECEPTOR CLASS B TYPE I
IN THYMOPOIESIS

T cells, which constitute an essential arm in the adaptive immunity,
complete their development in the thymus through a process called
thymopoiesis. However, thymic involution can be induced by a couple of factors,
which impairs T cell functions and is slow to recover. Therefore, understanding
how thymopoiesis is regulated may lead effort to accelerate thymic recovery and
improve immune functions in thymocyte-depleted patients. In this project, we
identified scavenger receptor BI (SR-BI), a high density lipoprotein (HDL)
receptor, as a novel modulator in thymopoiesis. In mice, absence of SR-BI
causes a significant reduction in thymus size after puberty and a remarkable
decrease in thymic output. Consequently, SR-BI-null mice show a narrowed
naïve T cell pool in the periphery and blunted T cell responses, indicating that the
impaired thymopoiesis due to SR-BI deficiency leads to compromised T cell
homeostasis and functions. The impaired thymopoiesis of SR-BI-null mice is
featured by a significant reduction in the percentage of earliest T progenitors
(ETPs) but unchanged percentages of other thymocyte subtypes, suggesting that
SR-BI deficiency causes a reduction in progenitor thymic entry. Further
investigations reveal that SR-BI deficiency impairs thymopoiesis through
affecting bone marrow progenitor thymic homing without influencing the lymphoid
progenitor development in bone marrow. Importantly, SR-BI-null mice exhibit
delayed thymic recovery after sublethal irradiation, indicating that SR-BI is also
required for thymic regeneration. Using bone marrow transplantation models, we
elucidate that it is non-hematopoietic rather than hematopoietic SR-BI deficiency
that results in the defects in thymopoiesis. However, SR-BI deficiency-induced
hypercholesterolemia is not responsible for the impaired thymopoiesis. Using
adrenal transplantation models, we found that absence of adrenal SR-BI is
responsible for the impaired thymopoiesis, as shown by that adrenalectomized
mice transplanted with SR-BI-null adrenal gland display reduced thymus size,
decreased percentage of ETPs and delayed thymic regeneration compared with

those transplanted with wild-type adrenal. Altogether, results from this study
elucidate a previously unrecognized role of SR-BI in thymopoiesis. We reveal
that SR-BI expressed in adrenal gland is critical in maintaining normal T cell
development and enhancing thymic regeneration, providing novel links between
adrenal functions and T cell development.
Keywords: T cell development, scavenger receptor class B type I, thymic
recovery, progenitor thymic homing, adrenal gland
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Chapter 1

Background

1.1 T cell development and homeostasis
1.1.1 Introduction to the immune system
The mammalian immune system can be divided into two branches: the
innate immune system and the adaptive immune system. The innate immune
system provides the first line of defense against invading pathogens, but is nonspecific to pathogens and unable to establish immunological memory. On the
contrary, the adaptive immune system is pathogen-specific and can create
immunological memory that mounts enhanced responses to pathogens upon reinfection [1, 2]. In the adaptive immune system, the two major players are B cells
and T cells. B cells primarily fight against infections by producing antibodies and
thereby play a key role in the humoral immunity. B cells can also act as antigenpresenting cells during immune responses [3]. In contrast, T cells are the central
player in cell-mediated immunity as T cells can directly kill cells infected with
intracellular pathogens or facilitate other cell types, including B cells, to fulfill their
immune functions [4, 5]. The detailed characteristics and functions of T cells are
discussed below.
1.1.2 Introduction to T cells
Distinguished from other lymphocytes, T cells bear T cell receptors
(TCRs) on their surface, which can recognize major histocompatibility complex
(MHC)-bound antigens and are highly diverse in binding specificity [6]. The
majority of T cells in the immune system express TCRs composed of α- and β-
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TCR chains and thus are known as the αβ T cells. In contrast, a minority of T
cells express TCRs formed by γ- and δ-TCR chains, which are known as γδ T
cells and exert distinct functions from αβ T cells [7, 8]. In this dissertation, T cells
will refer to the conventional αβ T cells unless otherwise stated.
Two major classes of T cells that have different effector functions are
distinguished by the surface co-receptors CD4 and CD8. CD8+ cells recognize
class I MHC molecules and can kill cells infected with intracellular pathogens.
Therefore, CD8+ cells are also called cytotoxic T cells or killer T cells. CD4+ T
cells recognize class II MHC molecules. These cells are able to provide essential
signals to help other immune cells during immune responses and thus are also
known as helper T cells [9, 10]. CD4+ T cells can be further divided into several
subtypes, such as Th1 cells, Th2 cells, Th17 cells and regulatory T cells. These
helper T cell subtypes secrete different cytokines and play various roles in
immune processes [11-13].
1.1.3 T cell homeostasis
Both CD4+ and CD8+ T cells contain three major populations, naïve cells,
memory cells and effector cells. Naïve T cells are T cells that have not
encountered their specific antigens and do not have functional activities. Naïve T
cells are characterized by the presence of surface receptor L-selectin (CD62L)
[11, 14] and the absence of activation markers such as CD69, CD25 or CD44
[15, 16]. Circulating through peripheral lymphoid tissues, naïve T cells scan
MHC/peptide complexes on the surface of antigen presenting cells. Effector T
cells can perform T cell functions such as producing cytokines (for CD4+ cells) or
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invoking cell killing (for CD8+ cells). They can migrate to the site of infection and
directly participate in the removal of antigens [13, 17]. Memory T cells are
“experienced” T cells that have previously encountered their cognate antigens
and are characterized by the expression of surface marker CD44. Memory T
cells can be further divided into two major groups, central memory T cells and
effector memory T cells. Central memory T cells express homing receptors, such
as CD62L and C-C chemokine receptor type 7 (CCR7), that allow cells to migrate
to secondary lymphoid organs. These cells are able to self-renew, but lack
immediate effector functions. In contrast, effector memory T cells express
molecules required for homing to inflammation tissues and have rapid effector
functions [18, 19].
The numbers of naïve T cells, effector T cells and memory T cells are
tightly regulated by complex homeostatic mechanisms to ensure optimal immune
responses to antigens as well as reduce a risk of damaging self-tissues (Figure
1.1) [13]. Under normal conditions, naïve T cell numbers are maintained in a
relatively constant level. Because naïve T cells are long-lived cells that rarely
proliferate [20], their homeostasis in the periphery is mainly maintained by
controlling survival. Naïve T cells depend on extrinsic signals such as selfpeptide+MHC complexes and interleukin-7 (IL-7) to survive [21-24]. Though new
T cells are produced continuously from the thymus, all naïve T cells compete for
the limited survival signals and a balanced number of naïve T cells are removed
by apoptosis [13, 25]. Meanwhile, naïve T cells can give rise to a number of
memory-phenotype T cells through a process called homeostatic proliferation.
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The homeostatic proliferation of naïve T cells may reflect naïve T cell responses
to self-antigens and is responsible for the progressive accumulation of memory T
cells as age increases [26]. Unlike naïve T cells, memory T cells are proliferative.
Their survival relies on IL-7 and interleukin-15 (IL-15) but not on selfpeptide+MHC complexes [21, 27, 28]. Also, the degree of death appears to
balance with the cell division to keep the size of memory cells relatively steady
under normal circumstances [13, 26].
When the body is invaded by a pathogen, the specific naïve T cells
recognize the peptide/MHC complexes on antigen presenting cells and then
become activated. Activated T cells undergo clonal expansion, giving rise to
thousands of effector T cells with identical binding specificity, which then migrate
to the inflammation site to exert their functions. T cell-mediated immune
responses are also tightly controlled. On one hand, a small group of effector T
cells differentiate into regulatory T cells, which can suppress immune responses
and prevent autoimmune problems [29]. On the other hand, after the antigen is
cleared, the majority of effector T cells are rapidly removed by apoptosis to avoid
damage to self tissues. Only a small group of effector T cells are retained to
develop into memory T cells [30-32]. If the memory T cells are exposed to the
same antigen, they can rapidly produce a large number of effector T cells,
providing a quicker and stronger secondary immune response to clear the
invading pathogen [13].

4

1.1.4 Thymopoiesis
T cells complete their development in the thymus, an organ located
anatomically in the anterior superior mediastinum. Generally speaking, cells in
the thymus, i.e. thymocytes, can be divided into two major groups, T-lineage cells
and stromal cells. Thymic T-lineage cells are cells being “educated” in the
thymus. They develop from bone marrow-derived precursors to mature naïve T
cells, constituting a majority of thymocytes. Thymic stromal cells include thymic
epithelial cells, thymic endothelial cells, dendritic cells and macrophages, which
are important in providing a specialized environment to instruct T cell
development [33, 34].
Bone marrow-derived progenitors undergo a complex developmental
program in the thymus to generate mature naïve T cells (Figure 1.2). The most
original T-lineage cells in the thymus are the earliest T progenitors (ETPs), which
are derived from bone marrow precursors that enter the thymus via the
circulation. ETPs lack most of the surface molecules characteristic of mature T
cells but express high levels of the cytokine receptor Kit (cKit or CD117) [35, 36].
After settling in the thymus, ETPs start to proliferate and give rise to downstream
T lineage cells. Thymocytes in the early developmental stage including ETPs do
not express CD4 or CD8. Thereby these cells are called double negative (DN)
thymocytes. During the DN stage of thymopoiesis, T-lineage cells temporarily
express surface marker CD25 and down-regulate CD44 expression. Thus, based
the expression of CD44 and CD25, the DN cells are further divided to four
groups, that is, from immature to mature, CD44+CD25- (DN1) cells, CD44+CD25+
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(DN2) cells, CD44-CD25+ (DN3) cells and CD44-CD25- (DN4) cells. DN1 cells
are highly heterogeneous which include ETPs and a variety of non-T-lineage
cells. In contrast, nearly all of DN cells in other three stages are T-lineage cells
[13, 37, 38]. The rearrangement of TCR-β chain locus occurs in DN2 and DN3
stage. Only thymocytes with successful β chain rearrangements can progress to
DN4 stage. This process is regarded as the first checkpoint of T cell
development, which is called β selection [39].
Thymocytes passing β selection begin to express CD4 and CD8 to
become double positive (DP) thymocytes, which comprise the majority (>80%) of
thymocytes [13, 37, 38]. During the DP stage, the TCR-α locus rearranges and a
selection process called positive selection occurs. In positive selection,
thymocytes are screened for their recognition of MHC molecules. DP thymocytes
without a TCR capable of binding MHC molecules are removed by apoptosis. DP
thymocytes also undergo negative selection in which they are tested for their
reactivity to self-ligands. Cells with high reactivity to self-ligands are eliminated in
this selection process. Positive selection and negative selection ensure that only
T cells that contain functional TCRs and do not recognize self-antigens are
generated from the thymus [40]. DP thymocytes passing two selection processes
differentiate to CD4+ single positive (4SP) or CD8+ single positive (8SP) cells.
During the SP stage, thymocytes down-regulate proteins involved in selection
processes and begin expressing a series of markers involved in thymocyte
egress from the thymus or homing to secondary lymphoid organs. This process
is called SP thymocyte maturation [41, 42]. The mature SP thymocytes finally
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the egress from the thymus to blood as recent thymic emigrants (RTEs) to
maintain the naïve T cell pool [34].
1.1.5 Thymopoiesis and T cell homeostasis
Thymopoiesis plays an essential part in the homeostatic regulation of
naïve T cells (Figure 1.3). The contribution of thymopoiesis to maintaining the
naïve T cell pool size was revealed in mice or human beings whose thymopoiesis
was ablated. In mice, absence of thymopoiesis in mice causes a dramatically
decreased naïve T cell pool size and a reduced naïve T cell to memory T cell
ratio [43, 44]. The decay of the naïve T cell pool was also reported in
thymectomized human beings [45, 46]. The reduction of naïve T cells is thought
to be due to successive antigen stimulation that shifts naïve cells to memory cells
[44, 47].
More importantly, thymopoiesis plays a key role in replenishing the naïve
T cells to maintain a diverse TCR repertoire and optimal T cell functions. A
maximally diverse TCR repertoire of naïve T cells is essential for the efficient
generation of immune responses to new infections [48, 49]. However, during
antigen stimulation or homeostatic proliferation, the clone sizes and relative
clonal representation in TCR repertoire can be altered, causing a progressive
loss of diversity and accumulation of auto-reactive T cells [50-53]. The biased
TCR repertoire can be corrected by RTEs. The newly generated T cells have a
competition advantage over the old ones, replacing equal numbers of preexisting
naïve T cells in the pool [54]. Through injecting TCR transgenic cells into mice,
Tanchot et.al showed that in presence of thymic output, the gradually T cell
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substitution results in a decay of preexisting TCR transgenic cells, demonstrating
that the RTEs play a critical role in renewing the TCR repertoire [55]. The
absence or reduction of thymic output leads to a loss of TCR diversity and
accumulation of auto-reactive T cells, which is responsible for the compromised
immune responses and autoimmune disorders in thymectomized patients, and
aged people or mice [46, 56-59].
T cell production not only maintains TCR diversity, but also is required for
optimal naïve T cell functions. When thymopoiesis is absent and the naïve T cell
pool is not replenished, naïve T cells live longer and undergo proliferation in an
attempt to restore the size of the reduced pool [44, 60, 61]. In this process, T cell
function is compromised. In aged or thymectomized mice, T cells show a
decreased functional avidity, defective stimulation-induced signaling as well as
blunted responsiveness to stimulation [62-64]. Increasing thymopoiesis in aged
animals can improve their peripheral T cell functions [65-67]. These observations
revealed that thymopoiesis is essential in maintaining optimal T cell functions.
1.1.6 Lymphoid progenitor development and thymic homing
Due to a lack of self-renewal progenitors in the thymus, long-term
thymopoiesis depends on continuous settlement of bone marrow progenitors to
the thymus [54, 68, 69]. The thymic precursors originally derive from
hematopoietic stem cells (HSCs) residing in bone marrow, which are able to selfrenew and have the potential to generate all the blood cell types. HSCs are
positive for the molecule Sca-1 and cKit, and negative for surface expression of
markers found on mature cell types (lineage markers). Thus, they belong to Lin-
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Sca-1+cKit+ (LSK) cells in bone marrow. Within LSK cells, HSCs are
characterized by the lack of CD135 expression [70, 71]. The first step in the
differentiation of HSCs involves the generation of multipotent progenitors
(MPPs). Compared with HSCs, MPPs lose the self-renewal capacity and only
maintain short-term multilineage reconstituting potential. MPPs also belong to
LSK cells but begin to express low levels of CD135 [72, 73]. MPPs then give rise
to lymphoid-primed multipotent progenitors (LMPPs), which start to express
lymphoid-specific genes and are more committed to lymphoid development.
LMPPs are still Lin-Sca-1+cKit+, but distinguished from HSCs and MPPs by their
high levels of CD135 expression [74]. LMPPs in turn produce common lymphoid
progenitors (CLPs), which possess high lymphoid potential with limited myeloid
potential. Compared with their upstream progenitors, CLPs display elevated IL-7
receptor α (IL-7Rα) expression and reduced Sca-1 and cKit expression [75, 76]
(figure 1.4).
Bone marrow progenitors can mobilize out of bone marrow into the
circulation and then migrate to the thymus through a process called progenitor
thymic homing (Figure 1.4) [34, 68]. Though all bone marrow progenitors can be
detected in blood [77], only LMPPs and CLPs have the ability to enter the thymus
and are closely related with the intrathymic precursors at the molecular level [78,
79]. Consequently, LMPPs and CLPs are believed as the direct ancestors of
thymic T-lineage cells. Due to the extremely low numbers of progenitors settling
to the thymus, the detailed mechanism of progenitor thymic settling is not
completely understood [80, 81]. However, a group of adhesive molecules and
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cytokines expressed in thymic endothelial cells, such as P-selectin, CCL21 and
CCL25, have been reported to mediate the entry of progenitor cells [68, 82].
Multiple mouse strains with disrupted progenitor thymic homing due to the
blockage of the adhesion cascade display reduced thymocyte numbers and
impaired thymopoiesis [83, 84], highlighting the essential role of progenitor
thymic homing in maintaining normal thymopoiesis.
1.1.7 Age-related thymic involution
Despite being the main site for T cells development, thymus mass and
thymic cellularity begins to decrease after adolescence [85-87]. This
phenomenon is known as age-related thymic involution. This thymus regression
is an evolutionary conserved event, as it occurs in nearly all vertebrates that
have a thymus [88]. The age-related thymic involution is characterized by a
systematic loss of thymocytes without an obvious blockade in thymocyte
differentiation [89]. It has been showed that age-related thymic involution leads to
reduced T cell production [90, 91]. Consequently, aged people or mice display a
restricted naïve T cell pool, a skewed TCR repertoire and impaired T-cell
functions [62, 87, 92, 93], which are believed at least partly responsible for the
impaired immune response to newly encountered antigens and increased
susceptibility to infections [62, 92]. The reason why the thymus involutes in the
elderly has not been fully elucidated, but multiple defects have been suggested
to underlie age-related thymic involution, including the loss of developmental
potential in aged bone marrow cells[94]; the decline in ETPs and their
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proliferative potential [94, 95]; and decreased numbers and altered structure of
thymic epithelial cells (TECs) [96-99].
1.1.8 Thymocyte depletion and thymic recovery
In addition to age-related thymic involution, the thymus can also undergo
transient and reversible regression under certain circumstances [100]. Transient
thymic regression is called acute thymic involution, and is characterized by
enhanced thymocyte death and acute loss of DP thymocytes [100-103]. Naturally
occurred acute thymic involution is usually associated with stress, under
conditions such as infections [104], malfunction [105] and pregnancy [106]. Some
therapeutic processes, such as clinical cancer treatments or preparative
regimens for bone marrow transplant, can also cause acute thymic involution
[102, 107, 108]. Similar to age-related thymic involution, acute thymic involution
results in a disrupted thymopoiesis, which is considered deleterious as it
decreases the likelihood of infectious agent being cleared and increases the risk
of infections by newly encountered antigens [89, 107, 109, 110]. Moreover, the
thymic recovery after lymphocyte depletion is a prolonged process, which is the
primary obstacle to reconstitute peripheral T cell pool and immune responses in
thymic depleted patients [102, 107, 111-113]. How thymic involution is induced
and how thymic recovery is regulated still remains incompletely understood [102].
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Figure 1.1 Regulation of T cell homeostasis.
Under normal circumstances (top), the naïve T cell pool size is maintained by T
cell production from the thymus and balanced cell death of existing naïve T cells.
In addition, naïve T cells can undergo homeostatic proliferation and be converted
to memory T cells. In contrast, the memory T cell pool is mainly maintained by
proliferation. During immune responses (middle), naïve T cells are activated and
generate large numbers of effector T cells, which can migrate to the inflammation
site to fight against pathogens. If the antigen is not new, memory T cells can also
generate effector T cells in a quicker and stronger manner. When the antigen is
removed (bottom), most effector T cells undergo apoptosis to avoid damages to
self-tissues. A small number of effector T cells develop to memory cells to protect
against secondary invasions.
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Figure 1.2 T cell development in the thymus.
Bone marrow-derived precursors arrive in thymus as earliest thymic
progenitors(ETPs), which then develop from double negative stages(DN; CD4CD8-) to double positive stages(DP; CD4+CD8+) after being screened for the
expression of pre-TCR(β selection). DP cells undergo positive selection to delete
cells without effective TCR and negative selection to remove cells interact with
self-antigens, followed by differentiating into single positive (SP; CD4+CD8- or
CD4-CD8+) cells. SP cells, after maturation, exit the thymus as recent thymic
emigrants (RTEs).
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Figure 1.3 Consequences of the impaired thymopoiesis.
Adequate T cell production is essential for maintaining a normal naïve T cell pool
size, maximal TCR diversity and optimal T cell responses (upper). Inadequate T
cell production leads to decreased naïve T cell numbers, restricted TCR
repertoire and impaired T cell responses (bottom).
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Figure 1.4 Thymic progenitor development and homing.
Thymic progenitors originally derive from hematopoietic stem cells (HSCs) in
bone marrow. To generate thymic progenitors, HSCs give rise to multipotent
progenitors (MPPs), which then develop to lymphoid-primed multipotent
progenitors (LMPPs). HSCs, MPPs and LMPPs are all subgroups of LSK (Lin Sca-1+cKit+) cells. LMPPs can further develop to common lymphoid progenitors
(CLPs). LMPPs and CLPs are able to settle in the thymus via the circulation
through a process called progenitor thymic homing, followed by the generation of
downstream thymocytes.
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1.2 Scavenger receptor class B type I
1.2.1 Overview of SR-BI
Scavenger receptor class B type I (SR-BI) is a 509-amino acid
transmembrane protein belonging to the class B scavenger receptor family. As
with CD36 and lysosome membrane protein 2 (LIMP2), the other members of
this family, SR-BI has a horseshoe-like structure with short N- and C-terminal
cytoplasmic domains, two transmembrane domains and a large heavily Nglycosylated extracellular loop (Figure 1.5) [114, 115]. The extracellular domain
of SR-BI is predicted to contain a helical bundle which binds with ligands and a
tunnel used for substrates delivery [116]. SR-BI also has a splice variant, SR-BII,
which differs from SR-BI in its carboxyl terminal and serves as another member
of class B scavenger receptor family [117].
Like many other scavenger receptors, SR-BI can recognize a wide range
of self- and foreign ligands (Figure 1.5) [118-121]. The self-originated ligands of
SR-BI include modified low density lipoprotein (LDL), naïve LDL, high density
lipoprotein (HDL), maleylated bovine serum albumin (BSA), anionic
phospholipids and apoptotic cells [122-125]. The non-self-ligands include
lipopolysaccharide (LPS), lipoteichoic acid (LTA), gram-negative bacteria, grampositive bacteria and soluble hepatitis c virus (HCV) E2 glycoprotein [126-128].
SR-BI is most abundantly expressed in liver, adrenal gland and ovaries, which is
closely related with its major functions (discussed in detail below) [125, 129,
130]. SR-BI is also expressed many other cell types, such as endothelial cells
[131], epithelial cells [132], macrophages [133] and lymphocytes [134]. The wide
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range of ligands SR-BI can bind and the diverse tissues SR-BI is expressed
underlie the multiple functions of SR-BI within the body [135].
1.2.2 Classical function of SR-BI in HDL metabolism
HDLs are the smallest and most dense group of lipoproteins in plasma
[136]. HDLs are highly heterogeneous, as they vary in diameter, density and
composition [137, 138]. The basic structure of HDLs include two major parts, a
core made of hydrophobic lipid, such as cholesteryl ester and triglyceride, and a
surface monolayer of phospholipid, free cholesterol and apolipoproteins [138,
139]. HDL cholesterol (HDL-c) is recognized as “good” cholesterol, as it is well
documented that the concentration of HDL-c in blood is inversely associated with
the risk of cardiovascular diseases [140, 141]. Intense researches on the
metabolism and functions of HDLs have revealed that they can exert multiple
atheroprotective functions, including mediating cholesterol transportation[142,
143], anti-inflammation[144-146], and anti-oxidation [147, 148].
An essential mechanism by which HDLs protect against cardiovascular
disease is mediating cholesterol transport from peripheral tissues via reverse
cholesterol transport (RCT) [149]. Due to the inability to degrade cholesterol,
peripheral cells must transport excess cholesterol to the liver to prevent
cholesterol accumulation. RCT is the process by which HDLs take away
cholesterol from peripheral tissues and transport cholesterol to the liver for
excretion [150]. Blockage of RCT causes cholesterol accumulation in peripheral
tissues, which leads to elevated risk for arthrosclerosis [151]. In addition to
transporting cholesterol to the liver, HDLs are also responsible for delivering
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cholesterol to steroidogenic tissues, such as the adrenal gland, providing
cholesterol as sources for steroid synthesis [152-154].
In 1996, SR-BI was identified as the first HDL receptor as it was reported
that SR-BI not only binds HDL but also mediates selective cholesterol uptake
from HDL [125]. Later it was confirmed that SR-BI is a physiological HDL
receptor. In mice, overexpression of SR-BI decreases plasma HDL levels [155]
and the deficiency of SR-BI causes hypercholesterolemia and accumulation of
large HDL particles in the circulation [156]. In humans, SR-BI mutations also lead
to elevated HDL concentrations in plasma and altered cholesterol metabolism in
macrophages [157, 158]. Nowadays, it has is well known that SR-BI is a key
mediator in HDL metabolism and plays multiple roles in RCT (Figure 1.6) [159,
160].
The primary role of SR-BI in RCT is that it is the sole molecule mediating
cholesterol uptake from HDL in the liver, where SR-BI is most abundantly
expressed [125, 161-163]. In this process, cholesterol and other lipids are
selectively delivered to cells without endocytosis or degradation of lipoprotein
particles [164, 165]. Consequently, this process is called selective cholesterol
uptake. Hepatic SR-BI-mediated selective uptake is a key determinant of the
efficiency of RCT, as revealed by hepatic overexpression of SR-BI decreases
plasma HDL-c concentration and increases biliary cholesterol secretion [155,
166, 167]; hepatic-specific down-regulation or knockout of SR-BI elevates
plasma HDL-c levels [168-170]. SR-BI also plays a role in mediating selective
cholesterol uptake in steroidogenic tissues, such as the adrenal gland [161].
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Adrenal SR-BI-mediated selective uptake is essential for adrenal
steroidogenesis, which is highlighted by recent findings that adrenal-specific
disruption of SR-BI in mice results in glucocorticoid insufficiency [171].
HDL takes cholesterol from peripheral tissues in interstitial space and then
delivers cholesterol to the liver via blood. Thus, in RCT, HDL needs to travel
between interstitial fluid and blood to deliver cholesterol. Recent publications
indicate that SR-BI is involved in HDL transport. To enter the interstitial fluid,
lipid-poor HDL in blood crosses aortic endothelial cells by transcytosis [172, 173].
Silencing SR-BI in endothelial cells decreases the binding of HDL by 50% and
reduces HDL transcytosis, indicating that endothelial SR-BI participates in this
movement [173]. After loading cholesterol from peripheral cells, lipid-rich HDL
returns to blood via lymphatic vessels [174, 175]. Lymphatic endotheliumexpressed SR-BI mediates the uptake and transcytosis of HDL to lymphatic
vessels. Blocking SR-BI significantly reduces the transport of HDL from the
periphery to blood in mice [174], indicating that SR-BI is an essential determinant
in the process that returns HDL to blood .
SR-BI plays a role in mediating free cholesterol efflux from peripheral cells
to HDL. The role of SR-BI in cholesterol efflux was elucidated by the
observations that in cell lines, the cholesterol efflux rate from cells to HDL
correlates with the SR-BI expression levels [176, 177], and macrophages from
SR-BI-deficient mice or patients carrying functional SR-BI mutations display
reduced capability of effluxing cholesterol to HDL [157, 178]. However, one group
reported that SR-BI deficiency in macrophages does not impair RCT in vivo

20

[179]. How SR-BI-mediated cholesterol efflux in macrophages and other cell
types physiologically affects RCT still remains incompletely understood.
1.2.3 SR-BI and atherosclerosis
As SR-BI is a key player in RCT, it is not surprising that SR-BI plays a
protective role against atherosclerosis. The systemic role of SR-BI in protecting
against atherosclerosis was demonstrated by manipulating SR-BI expression in
animal models. In mice, modest SR-BI overexpression decreases the
development of the diet-induced fatty streak lesions [180], whereas attenuation
or ablation of SR-BI expression increases diet-induced aortic atherosclerosis
[178, 181, 182]. Moreover, the absence of SR-BI in apolipoprotein E (ApoE)deficient background spontaneously induces accelerated atherosclerosis, early
onset occlusive coronary artery disease, and premature death [183]. These data
clearly indicate a protective role of SR-BI against atherosclerosis.
Interestingly, though the atheroprotective effects of SR-BI are thought
mainly attributed to its roles in cholesterol transport, several other
atheroprotective properties of SR-BI are also identified [184-187]. For example,
SR-BI expressed in hematopoietic cells plays a role in protection against
atherosclerosis, since the absence of SR-BI expression in hematopoietic cells
leads to elevated atherosclerosis [178, 182, 188-190]. SR-BI expressed in
macrophages seems to provide the major atheroprotective effect, which is
supported by the observation that the absence of macrophage SR-BI impairs
cholesterol homeostasis [191] and exaggerates cytokine secretion in
macrophages [189, 192]. Meanwhile, SR-BI-facilitated bidirectional cholesterol
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efflux influences foam cell formation. Though hematopoietic SR-BI deficiency
alone does not cause foam cell accumulation, it exaggerates foam cell
accumulation when hematopoietic ATP-binding cassette transporter A1(ABCA1)
is absent, suggesting that SR-BI may serve as a compensatory route of
cholesterol efflux to decrease foam cell formation [190, 193].
HDL can also protect against atherosclerosis through its anti-oxidative
properties. This anti-oxidative benefit is mainly attributed to two HDL-bound
antioxidative enzymes, paraoxonase 1 (PON1) and platelet-activating factor
acetylhydrolase (PAF-AH) [139, 143, 148]. SR-BI deficiency decreases PON1
and PAF-AH activity, causing an increased oxidative stress in vivo [194]. In
addition, SR-BI was reported to participate in the pathway in which PON1 directly
dampens macrophage inflammatory responses [195], suggesting that SR-BI
deficiency may increase atherosclerosis through impairing anti-oxidative property
of HDL. SR-BI expressed in endothelial cells also contributes to reducing
atherosclerosis. Endothelial SR-BI not only mediates HDL-induced endothelial
cell migration and repair [196], but also induces the production of the antiatherogenic molecule NO in response to HDL [197, 198].
1.2.4 SR-BI as a multi-functional receptor
In addition to mediating cholesterol transport and protecting against
atherosclerosis, SR-BI is able to perform several other functions in multiple
systems. Currently identified roles of SR-BI include controlling induced steroid
production, preventing female infertility, maintaining normal erythropoiesis and
platelet functions, and a series of functions in immunity.
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SR-BI-mediated selective cholesterol uptake from HDL is an essential
pathway to supply exogenous cholesterol to the adrenal gland [161, 199-202],
which is shown by the depletion of cholesterol storage in adrenal gland of SR-BIdeficient mice [156]. Because of the existence of other pathways that can supply
cholesterol to adrenal, such as endogenous cholesterol synthesis [203] and LDL
receptor-mediated cholesterol uptake [204], the adrenal functions of SR-BI-null
mice appear unaffected under normal conditions [205-207]. However, the
deficient mice exhibit a lack of inducible glucocorticoid production in response to
ACTH or stress [206-208], indicating that SR-BI-mediated cholesterol uptake is
required for inducible glucocorticoid production. Patients carrying missense
mutations of SR-BI also display marked reductions in urinary steroid secretion
and decreased responses to corticotrophin stimulation, indicating that SR-BI is
also essential in maintaining normal adrenal function in humans [157].
The absence of SR-BI in mice also causes female infertility which is
believed to be a result of the defective oocytes that display abnormal morphology
and arrested development in vitro [209]. Meanwhile, the SR-BI deficiencyinduced abnormal HDLs are also linked to the female infertility. Normalization of
the HDL particles in SR-BI-/- mice by disrupting apolipoprotein A-I (apoA-I),
probucol treatment or hepatic SR-BI expression relieves the female infertility [210,
211]. In contrast, in spite of the lipid storage depletion [209], SR-BI-null ovaries
are not responsible for the female infertility, since SR-BI-/- ovaries transplanted to
ovariectomized SR-BI+/+ mice display normal functions[210].
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The loss of SR-BI in mice leads to abnormalities in erythrocytes and
platelets. For erythrocytes, SR-BI-deficient mice show accumulation of
reticulocytes in the circulation and a blockage in erythrocyte development in
spleen [212, 213]. For platelets, SR-BI deficiency causes abnormal platelet
morphologies, elevated rates of platelet clearance from the circulation and a
defect in ADP-induced platelet aggregation in mice [214-216]. The abnormalities
in erythrocytes and platelets are at least partly induced by the SR-BI deficiencyinduced hypercholesterolemia; and are thought to be the reason for anemia and
increased susceptibility to thromobosis [212, 214, 217].
1.2.5 Roles of SR-BI in immunity
SR-BI-deficient mice exhibit several phenotypic changes in the immune
system (Figure 1.7), such as increased susceptibility to septic death, impaired
lymphocyte homeostasis and reduced HCV infection [135]. Based on these major
immunological phenotypes, multiple functions of SR-BI in immunity have been
discovered in recent years.
A well-documented role of SR-BI in immunity is in protection against septic
death. SR-BI deficiency causes significantly elevated death rate in sepsis, as
shown by our observations that LPS injection induced 90% fatality in SR-BIdeficient mice, whereas all wild-type littermates survived [218]; and cecal ligation
and puncture (CLP) induced 100% fatality in SR-BI-deficient mice, compared
with 21% fatality in controls [207]. In addition to the increased death rate, during
sepsis, SR-BI-/- mice have multiple defects including uncontrolled inflammatory
cytokine production, delayed LPS clearance and augmented tissue damage [206,
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207]. These observations indicate that SR-BI provides essential protection
against sepsis.
Further investigations revealed that SR-BI can exert multiple protective
functions against septic death [135]. The primary leading factor to the elevated
mortality in sepsis of SR-BI-/- mice is thought to be the impaired inducible steroid
synthesis in the adrenal gland. After LPS injection, supplementation of
corticosterone in drinking water normalizes cytokine production and rescues
survival rate of SR-BI-/- mice; and adrenalectomy abolishes the differences in
inflammatory cytokine production between wild-type and SR-BI-deficient mice
[206]. Under CLP challenge, though corticosterone supplementation in drinking
water does not increase the survival rate of SR-BI-/- mice [207], adrenalectomized
SR-BI+/+ mice transplanted with SR-BI-/- adrenal show higher fatality than those
transplanted with SR-BI+/+ adrenal, suggesting that the insufficiency of multiple
adrenal-derived steroids instead of corticoids alone is responsible for decreased
survival rate during sepsis [219].
SR-BI deficiency also leads to elevated macrophagic inflammatory
responses in mice [192, 207]. Hematopoietic SR-BI deficiency causes higher
cytokine productions in response to LPS, indicating that macrophage SR-BI
helps control inflammatory responses in vivo.[192]. The uncontrolled
inflammatory responses of macrophages are a contributing factor to the elevated
septic death of SR-BI-null mice, as shown by that overexpression of an SR-BI
mutant in SR-BI-deficient mice, which normalizes macrophagic cytokine
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production without restoring corticosterone generation, significantly improves
their survival under CLP challenge [207, 220].
As a scavenger receptor able to recognize foreign ligands, SR-BI can bind
LPS and mediate its removal [126]. Hepatocytes from SR-BI-null mice display a
decreased ability to uptake LPS in vitro, resulting in decreased hepatic LPS
uptake and increased plasma LPS retention after LPS injection in vivo [206]. In
the CLP model, SR-BI-deficient mice also show higher plasma LPS
concentrations, providing further support that SR-BI deficiency decelerates LPS
clearance [207]. Interestingly, during early stages of sepsis, SR-BI-deficient mice
display lower plasma LPS concentrations than their wild-type counterparts,
suggesting that SR-BI-mediated LPS uptake may also be essential for
transporting LPS from the inflammation site to blood [207]. ScarbII179N mice,
whose SR-BI expression is specifically decreased by 90% in the liver [168], show
elevated mortality under CLP challenge associated with impaired hepatic LPS
uptake, but normal corticosterone production and macrophagic inflammatory
response, indicating that the SR-BI-mediated hepatic LPS uptake is also critical
in protecting against septic death [221]. In addition, SR-BI can also protect
against NO-induced cytotoxicity. The lack of SR-BI-mediated protection against
NO-induced cytotoxicity is believed to be responsible for the increased tissue
damage during sepsis [218].
Though its functions are mostly considered beneficial, SR-BI is utilized by
HCV in the process of cell entry [222]. The involvement of SR-BI in HCV entry
was elucidated by the fact that down-regulating or blocking SR-BI in hepatocytes
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decreases HCV infectivity in vitro [223-227] and the deficiency or blockage of
SR-BI in humanized mice reduces HCV infection in vivo [228-230]. Therefore,
SR-BI is regarded as a promising target to treat HCV infection [231].
Initially it was thought SR-BI mediates HCV entry through direct binding
[128]. However, later research indicated that HCV entry involves the lipid transfer
functions of SR-BI [222, 232-235] but is probably not dependent on the SR-BIHCV binding [228, 235, 236]. Notably, SR-BI may be important in initiating the
host defense during HCV infection because dentritic cells also depend on SR-BI
to uptake HCV [237]. The detailed role of SR-BI in HCV infection and how this
receptor can be used to prevent HCV infection requires further investigation.
1.2.6 SR-BI and adaptive immunity
In recent years, several players in RCT, including ApoA-I, ATP-binding
cassette transporter G1 (ABCG1) and Liver X receptor (LXR) have been
identified as modulators in adaptive immunity [139, 238-242]. For example, the
absence of ApoA-I, the major protein in HDL [136, 243] induces cholesterol
accumulation in T cells, causing T cell expansion and hyperactivation in skin
lymph nodes associated with an autoimmune phenotype in LDL receptor (LDLR)deficient mice fed with an atherogenic diet [239, 240]. Similarly, deficiency of
ABCG1, a key transporter mediating cholesterol efflux in RCT [244, 245], causes
increased cholesterol accumulation in T-lineage cells, resulting in increased
thymocyte and peripheral T cell proliferation in mice [241]. Our group
investigated the role of SR-BI in adaptive immunity using SR-BI-deficient mice
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and were the first to report that the loss of SR-BI causes impaired lymphocyte
homeostasis [134].
SR-BI-deficient mice display significant lymphocyte expansion in spleen
resulting in significantly enlarged spleen sizes. Notably, the lymphocyte
expansion is imbalanced, as SR-BI-deficient mice exhibit a 30% decrease in the
T/B cell ratio. Meanwhile, the SR-BI deficiency also causes lymphocyte
hyperactivation and hyperproliferation. As a consequence of the impaired
lymphocyte homeostasis, aged SR-BI-deficient mice suffer from profound
autoimmune disorders. With these data, we demonstrated that SR-BI is essential
in maintaining lymphocyte homeostasis and preventing autoimmunity [134].
The adaptive immune defects of SR-BI-deficient mice are at least partly
attributed to their abnormal HDL, which is larger in size and characterized by the
accumulation of free cholesterol [156]. Functionally, SR-BI-deficient HDL shows
a reduced ability to mediate selective cholesterol uptake [246], decreased antioxidative enzyme activity [194], and is responsible for female infertility [210, 211].
We found that the dysfunctional HDL from SR-BI-null mice partly loses the
inhibitory effects on anti-CD3-stimulated T cell proliferation and LPS-induced B
cell proliferation of normal HDL, indicating that SR-BI can indirectly influence
lymphocyte function through regulating HDL properties [134]. Intriguingly, we
recently reported that HDL from SR-BI-deficient mice is also dysfunctional in
enhancing glucocorticoid-induced thymocyte apoptosis, which contributes to the
increased septic death of SR-BI-null mice, providing another clue of how HDL
functions in adaptive immunity [247].
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The mechanism by which normal/dysfunctional HDL modulates
lymphocyte proliferation is not yet fully understood. Several pieces of evidence
have implied that HDL may affect lymphocyte proliferation through regulating its
cholesterol contents, as seen in leukocytes [139] and hematopoietic progenitors
[248]. Bensinger et al. reported that during T cell activation, the LXR pathway
controlling cholesterol export is suppressed and the pathway controlling
cholesterol synthesis is induced, suggesting that T cell cholesterol homeostasis
is altered during the activation process [242]. Pharmaceutically activating LXR
pathways inhibits activation-induced T cell proliferation while absence of LXRβ
causes a proliferative advantage of T cells [242]. Importantly, LXR modulates T
cell function via ABCG1, the transporter mediating cholesterol efflux from cells to
HDL [242]. The ABCG1 deficiency also causes increased proliferation of T cells
in mice [241], together suggesting that ABCG1-mediated cholesterol efflux to
HDL inhibits T cell proliferation. In SR-BI-deficient mice, the HDL may be
dysfunctional in acquiring cholesterol from lymphocyte via ABCG1, which causes
the proliferative advantage. Further investigations are warranted to test this
possibility.
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Figure 1.5 General structures and ligands of SR-BI.
SR-BI has a horse-shoe structure with two short intracellular domains, two
transmembrane domains and a large extracellular loop. It can bind a variety of
self-molecules or microbial ligands.
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Figure 1.6 Multiple roles of SR-BI in RCT.
In RCT, HDL loads cholesterol from peripheral tissues (shown as macrophage in
figure) via ATP-binding cassette transporters and delivers cholesterol to liver for
disposal or to steroidogenic tissues, such as adrenal gland, for steroidogenesis.
The roles SR-BI plays in RCT including 1, mediating selective cholesterol uptake
in liver or steroidogenic tissues; 2, facilitating cholesterol efflux in peripheral
tissues and 3, mediating HDL transport between blood and interstitial fluid.
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Figure 1.7 Major immune phenotypes of SR-BI-deficient mice.
SR-BI deficiency causes several defects in immunity including increased
susceptibility to atherosclerosis, elevated susceptibility to sepsis and impaired
lymphocyte homeostasis (shown in red). SR-BI deficiency also has beneficial
effects in mice as it decreases HCV infection (shown in green) [135].
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1.3 Synopsis of the project
During the past few years, our group has been intensively working on
investigating the multiple roles of SR-BI in immunity. We were the first to report
that SR-BI-deficient mice have impaired lymphocyte homeostasis and that SR-BI
deficiency-induced dysfunctional HDL is the leading cause of lymphocyte
expansion, hyperactivation and hyperproliferation [134, 135]. However, as the
SR-BI-null HDL is dysfunctional in inhibiting the stimuli-induced proliferation of
both T cells and B cells, it is not likely responsible for the decrease in T cell/ B
cell ratio. Thus, SR-BI should play additional roles in maintaining lymphocyte
homeostasis in addition to preventing lymphocyte expansion by keeping normal
HDL functions.
In an effort to identify the additional roles of SR-BI in adaptive immunity,
we focused on T cell development. Interestingly, by comparing the phenotypes of
SR-BI-null mice with mice whose T cell production is decreased, we found that in
addition to the decrease in T cell/B cell ratio, several other phenotypes of SR-BInull also potentially result from reduced T cell production, including the
decreased percentage of naïve T cells, blunted T cell response to stimuli and
autoimmune problems. These observations led us to hypothesize that SR-BI
deficiency causes impaired thymopoiesis, which contributes to the lymphocyte
imbalance in SR-BI-null mice. In chapter 3, we tested this hypothesis by
evaluating thymus size and thymic output. We observed significantly reduced
thymus size and markedly declined thymic output in SR-BI-null mice, clearly
indicating that SR-BI deficiency impairs thymopoiesis in mice. Importantly, by
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assessing peripheral T cells and their function in young age SR-BI-null mice, we
elucidated that SR-BI deficiency also impairs T cell homeostasis and responses,
demonstrating that SR-BI plays a role in maintaining lymphocyte homeostasis by
maintaining an optimal T cell production.
Next, we sought to elucidate the mechanism by which SR-BI deficiency
impaired thymopoiesis. As the first step, described in chapter 4, we analyzed
thymocyte subtypes in SR-BI-null mice in order to understand which steps of
thymopoiesis SR-BI plays a role in. We observed that SR-BI-null mice do not
show any significant change in the percentages of thymocyte subtypes except for
a remarkable decrease in the portion of ETPs, suggesting that SR-BI deficiency
reduces the progenitor entry into the thymus but does not influence other
downstream steps in thymopoiesis. To determine whether or not SR-BI
deficiency affects progenitor entry into the thymus, we analyzed bone marrow
progenitor development and progenitor thymic homing, two major steps upstream
of ETPs in T cell development, in SR-BI-null mice. Although we did not detect
any defect in progenitor development in the absence of SR-BI, we found that
fewer circulating bone marrow progenitors settle into the thymus in SR-BI-null
mice, demonstrating that SR-BI deficiency impairs thymopoiesis though
impacting bone marrow progenitor thymic homing. As SR-BI-null mice display
decreased percentage of ETPs and impaired progenitor thymic homing, we
hypothesized that SR-BI deficiency leads to delayed thymic recovery after
thymocyte depletion. Using the sublethal irradiation model, we observed that SR-
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BI-null mice exhibit impaired thymic recovery, indicating SR-BI is also required
for thymic regeneration.
In chapter 5, we investigated how the absence of SR-BI induces defects in
T cell development. First, we utilized bone marrow transplantation models to
investigate the role of hematopoietic and non-hematopoietic SR-BI in
thymopoiesis. We found that non-hematopoietic SR-BI deficiency is the leading
factor to the impaired thymopoiesis whereas hematopoietic SR-BI deficiency
does not cause any disadvantages in T cell development. Next, to evaluate the
contribution of SR-BI deficiency-induced hypercholesterolemia to the impaired
thymopoiesis, we manipulated plasma cholesterol concentration in SR-BI-/- mice.
Exaggerating hypercholesterolemia of SR-BI-null mice does not worsen thymic
hypocellularity, nor does relieving hypercholesterolemia correct thymic
hypocellularity, indicating that the defects in thymus are not induced by SR-BI
deficiency-induced hypercholesterolemia. We also did not observe cholesterol
accumulation in thymic macrophages of SR-BI-null mice, excluding the possibility
that SR-BI deficiency induces impaired thymopoiesis through cholesterol
accumulation and the subsequent NLRP3 inflammasome activation. Interestingly,
using adrenal transplantation models, we found that mice with adrenal SR-BI
deficiency display reduced thymus size, declined ETP percentage and impaired
thymic regeneration, demonstrating that absence of SR-BI in adrenal is the
leading cause to the impaired thymopoiesis.
Taken together, we identified a previously unrecognized role of SR-BI in
thymopoiesis. We conclude that 1: SR-BI deficiency impairs bone marrow

35

progenitor thymic homing, which further causes reduced thymus size, decreased
ETP percentage, declined T cell production and delayed thymic recovery, 2: The
reduced T cell production induced by SR-BI deficiency impairs peripheral T cell
homeostasis and functions, and 3: Adrenal SR-BI plays a major role in
maintaining normal thymopoiesis and thymic regeneration.

Copyright © Zhong Zheng 2014
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Chapter 2

Materials and Methods

2.1 Mice
2.1.1 General information
SR-BI+/- (B6;129S2-Srb1tm1Kri/J), Rag-1-/- (B6.129S7-Rag1tm1Mom/J),
CD45.1(B6.SJL-Ptprca Pepcb/BoyJ), LDLR-/- (B6.129S7-Ldlrtm1Her/J) and
C57BL/6J mice were purchased from the Jackson Laboratory. Because of the
female infertility due to SR-BI deficiency [210], SR-BI-/- mice were generated by
breeding SR-BI+/- mice, and the SR-BI+/+ littermates were used as controls. Rag1-/-, CD45.1 and C57BL/6J mice were all maintained by sibling mating. Mice were
kept and bred in a temperature-controlled room with 12-hour light and 12-hour
dark diurnal cycle at the animal facility of the University of Kentucky. All mice
were housed in filter-topped cages and were fed a standard laboratory diet
(0.015% wt/wt cholesterol, 5.7% wt/wt fat, Harlan Tekland 2018) if not otherwise
stated. Animal care and experiments were all approved by the Institutional
Animal Care and Use Committee of the University of Kentucky.
2.1.2 Generation of SR-BI/Rag-1 double knockout mice
To generate SR-BI-/-Rag-1-/- mice, male SR-BI-/- mice and female Rag-1-/mice were first cross-bred to generate SR-BI+/-Rag-1+/- F1 offspring, which were
subsequently intercrossed to generate F2 offspring. SR-BI+/-Rag-1-/- mice in F2
offspring were selected and intercrossed. Generated SR-BI-/-Rag-1-/- and SRBI+/+Rag-1-/- offspring were used for experiments, while the SR-BI+/-Rag-1-/offspring were further intercrossed to maintain the strain.
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2.1.3 Generation of SR-BI-null mice in C57BL/6J background
Most SR-BI-null mice used in this project were in a C57BL/6J/129 mixed
background. However, these mice could not be used in bone marrow
transplantation or bone marrow transfer experiments together with CD45.1 mice
that were in the C57BL/6J background. Thus, we backcrossed SR-BI+/- mice with
C57BL/6J mice for more than 10 generations. After backcrossing, the SR-BI+/offspring were selected and intercrossed to generate SR-BI-/- and SR-BI+/+ mice
in C57BL/6J background.
2.1.4 Generation of SR-BI/LDLR double knockout mice
To generate SR-BI-/-LDLR-/- mice, male SR-BI-/- mice and female LDLR-/mice were first cross-bred to generate SR-BI+/-LDLR+/- F1 offspring, which were
subsequently intercrossed to generate F2 offspring. SR-BI+/-LDLR-/- mice in F2
offspring were selected and intercrossed. Generated SR-BI-/-LDLR-/- mice were
used for experiments, while SR-BI+/-LDLR-/- mice were further intercrossed to
maintain the strain.
2.1.5 Genotyping of mice
2.1.5.1 Preparation of tail genomic DNA
When necessary, the genotypes of mouse offspring were determined by
polymerase chain reaction (PCR) with tail genomic DNA before they were
weaned. Briefly, ~0.4cm tail tips were cut from mice at the age of 14-19 days
and digested with 100μL 0.4μg/μL proteinase K in 55˚C water bath for 16~18
hours. The digested tails were then centrifuged at 2,000 rpm for 5 min at room
temperature and heated at 95 °C for ten minutes to deactivate the proteinase K.
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The solution was diluted by 5-fold volume of ddH2O and centrifuged again at
2,000 rpm, 5 min at 4 °C. The supernatant containing the genomic DNA was
used as the template for PCR.
2.1.5.2 Preparation of liver genomic DNA
The genotypes of all experimental mice were confirmed using DNA from
liver tissues after mice were sacrificed. To isolate the genomic DNA,
approximately 30mg liver tissue was cut into small pieces and incubated with
600µL digestion buffer (116µL 0.5M pH=8.0 EDTA + 484µL Nuclei lysis solution
+ 4µL 20mg/mL proteinase K solution) in 55˚C water bath for 18-20 hours. After
digestion, the protein was precipitated by adding 200µL Protein Precipitation
Solution and incubating on ice for 5 minutes. The solution was then centrifuged
at 12,000rpm for 5 minutes at 4°C, before the supernatant was mixed with
isoproterenol at a ratio of 1:1. The mixed solution was centrifuged again at
12,000rpm for 5 minutes at 4°C. After the centrifuge, the pellet was washed with
70% ethanol and dissolved in 400µL ddH2O. The final solution contained the
genomic DNA and was used as the template for PCR.
2.1.5.3 PCR genotyping of SR-BI
SR-BI wild-type and knockout alleles in mice were amplified as described
previously [249]. The primer sequences for amplifying SR-BI alleles were 5'-GATGGG-ACA-TGG-GAC-ACG-AAG-CCA-TTC-T-3' (named as AB2) and 5'-TCTGTC-TCC-GTC-TCC-TTC-AGG-TCC-TGA-3' (named as AB3). The reaction
system was made of 10μL Taq Red Mix (Bioline), 1μL 10μM AB2 primer, 1μL
10μM AB3 primer, 1μL DNA template and 7μL ddH2O. The PCR machine
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settings were: step 1: 5 minutes at 95°C; step 2: 30 seconds at 95°C, 30 seconds
at 58°C, 2 minutes at 72°C, 35 cycles; step 3: 10 minutes at 72°C. After reaction,
PCR products were analyzed using 1.5% agarose gels. The 1.0kb amplified DNA
band was from the wild-type allele and the 1.5kb one was from the knockout
allele (Figure 2.1).
2.1.5.4 PCR genotyping of Rag-1
In the process of generating SR-BI-/-Rag-1-/- mice, Rag-1 alleles were
genotyped in mice. The protocol to amplify the Rag-1 alleles was modified from
the protocol suggested by Jackson Lab. Briefly, to amplify the wild-type allele of
Rag-1, two primers, 5'- GAG-GTT-CCG-CTA-CGA-CTC-TG -3' (named as
oIMR1746) and 5'- CCG-GAC-AAG-TTT-TTC-ATC-GT -3' (named as oIMR3104)
were used. The reaction system was made of 10μL Taq Red Mix, 0.5μL 10μM
oIMR1746 primer, 0.5μL 10μM oIMR3104 primer, 1μL DNA template and 8μL
ddH2O. The PCR machine settings were: step 1: 2 minutes at 95°C; step 2: 30
seconds at 95°C, 30 seconds at 58°C, 30 seconds at 72°C, 35 cycles; step 3: 2
minutes at 72°C. Later, PCR products were analyzed using 2.0% agarose gels. A
474 bp band was amplified if the wild-type Rag-1 allele was present (Figure 2.2).
The PCR reaction to amplify the mutant allele of Rag-1 was the same with
the one to amplify the wild-type allele except that a primer 5’-TGG-ATG-TGGAAT-GTG-TGC-GAG-3’ (oIMR8162) was used to replace oIMR1746. The
amplified DNA product from the mutant allele was 530bp (Figure 2.2).
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2.1.5.5 PCR genotyping of LDLR
In the process of generating SR-BI-/-LDLR-/- mice, LDLR alleles were
genotyped in mice. The protocol to amplify the LDLR alleles was modified from
the protocol suggested by Jackson Lab. Briefly, two primers used to amplify the
wild-type allele of LDLR were 5'- CCA-TAT-GCA-TCC-CCA-GTC-TT-3' (named
as oIMR3349) and 5'- GCG-ATG-GAT-ACA-CTC-ACT-GC-3' (named as
oIMR3350). Two primers used to amplifying the mutant allele of LDLR were
oIMR 3349 and 5'- AAT-CCA-TCT-TGT-TCA-ATG-GCC-GAT-C-3' (named as
oIMR0092). The reaction system was made of 0.5μL GoTaq (Promega), 4μL 5X
reation buffer (Promega), 0.4μL dNTP (Promega), 1.6μL Mg2+ (Promega), 0.5μL
10 μM oIMR0092, 0.5μL 10 μM oIMR3349, 0.5μL 10 μM oIMR3350, 1μL DNA
template and 11μL ddH2O. The PCR machine settings were: step 1: 3 minutes at
94°C; step 2: 30 seconds at 94°C, 1 minute at 65°C, 1 minute at 72°C, 35 cycles;
step 3: 2 minutes at 72°C. Later, amplified PCR products were analyzed using
2.5% agarose gels. A 167 bp band was amplified from wild-type LDLR allele and
a 350 band was amplified from the mutant LDLR allele (Figure 2.3).
2.2 Mouse treatments
2.2.1 BrdU injection
5-bromo-2'-deoxyuridine (BrdU) is an analog of thymidine which can be
integrated into newly synthesized DNA of cells during proliferation. BrdU that is
incorporated into the DNA can be detected with its specific antibody and thus can
be used to monitor cell proliferation in vivo and in vitro [250-252]. For in vivo
BrdU labeling, we gave mice two intraperitoneal injections of 1mg BrdU in 200μL
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sterile PBS. The injections were spaced 24 hours apart and 24 hours after the
second injection, the mice were sacrificed and the BrdU incorporation in cells
was detected (BrdU detection procedure described in chapter 2.3.5).
2.2.2 Bone marrow transplantation
Bone marrow transplantation was performed as described previously [253,
254]. Briefly, recipient mice (13~20 weeks) were maintained on antibiotic water
(4μg/mL sulfratrim) for one week before irradiation. Then, the recipient mice were
irradiated with two doses of 400Rads from a cesium source that was delivered 3
to 4 hour apart. After irradiation, 5 million bone marrow cells obtained from
femurs of 5~6-week-old donor mice (bone marrow cell isolation procedure
described in chapter 2.3.1.5) were suspended in 100μL PBS and injected via tail
vein into the irradiated recipient mice. After bone marrow transplantation, mice
were maintained on antibiotic water for another 4 weeks, and then changed on
regular water for 2 weeks before being sacrificed.
2.2.3 Short-term homing assay
The short-term homing assay is commonly used to investigate the thymic
progenitor settlement in mice [83, 255]. Briefly, 20 million bone marrow cells from
5-week-old SR-BI+/+ mice labeled with carboxyfluorescein succinimidyl ester
(CFSE, labeling procedure described in chapter 2.5) were suspended in 100μL
PBS and injected to non-irradiated 5-week-old SR-BI+/+ or SR-BI-/- mice via tail
vein. The mice were maintained on regular water and normal diet for two days
before analysis.
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2.2.4 Long-term homing assay
The long-term homing assay was conducted to study the contribution of
circulating bone marrow progenitors to thymopoiesis [255]. In this assay, 20
million bone marrow cells from 6-week-old CD45.1 mice suspended in 100μL
PBS were injected to non-irradiated SR-BI+/+ or SR-BI-/- mice in C57BL/6J
background (6~26 weeks) via tail vein. The mice were maintained on regular
water and normal diet for two weeks before analysis.
2.2.5 Sublethal irradiation
Sublethal irradiation in mice mimics the whole body irradiation in patients
which is a preparative regimen for hematopoietic stem cell transplantation and
causes acute thymic atrophy. Sublethal irradiation thus is widely used for
investigating thymocyte recovery after thymocyte depletion [111, 256, 257]. In
this project, 8~10-week-old mice were irradiated with a single dose of 450 Rads
from a cesium source. Then the irradiated mice were maintained on regular
water and normal diet for 4 days, 7 days or 14 days before analysis.
2.2.6 High fat diet feeding
The high fat diet used in this project contains 15.8% by weight fat, 1.25%
by weight cholesterol and 0.5% by weight sodium cholate (Harlan Tekland),
which is widely used for elevating cholesterol concentrations in mice [258, 259].
After being weaned at the age of 3 weeks, the mice were immediately fed with
the high fat diet. The mice fed on normal diet described in chapter 2.1.1 were
used as control.
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2.2.7 Probucol administration
Probucol is a cholesterol lowering drug [260, 261] which was reported to
relieve the hypercholesterolemia in SR-BI-/- mice and normalize several adverse
effects of SR-BI deficiency [210, 262]. Probucol (Sigma) was dissolved in ethanol
at 55°C water bath before being sprayed on normal diet at 0.2% by weight. Then
the probucol-added diet was dried for one week before use. After being weaned
at the age of 3 weeks, mice were immediately fed with the probucol diet. The
mice on normal diet described in 2.1.1 were used as control.
2.2.8 Adrenal transplantation
The procedure of adrenal transplantation was previously described [171,
263]. Briefly, at day 8 after birth, the donor mice (offspring of SR-BI+/- breeders)
were genotyped using tail tips. At day 9, the SR-BI+/+ or SR-BI-/- donor mice were
euthanized using CO2 and their adrenal glands were harvested. The SR-BI+/+
recipient mouse (10-12 weeks) was anesthetized by isoflurane inhalation. After
anesthetization, the adrenal glands of the recipient were removed bilaterally and
one donor adrenal gland was put under the right kidney capsule through a slit
made by tweezers. After the right kidney was returned, the incisions were
sutured. After the surgery, the recipient was maintained on water containing
0.9% NaCl, before they were used for experiments 6 weeks later.
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2.3 Flow cytometry
2.3.1 Preparation of single cell suspensions
2.3.1.1 Spleen
The spleens were isolated and weighed immediately after mice were
sacrificed. Isolated spleen (if the spleen was less than 100mg, the whole spleen
was used; otherwise, a 70-100mg piece of spleen was used) was placed in a
stomacher bag (Seward) in the presence of 10mL RPMI 1640 (Gibco) containing
5% FBS (Gibco) and disrupted using Stomacher 80 (Seward). Later, the
suspension was moved to a 50mL centrifuge tube (BD Biosciences) through a
100μm cell strainer (BD Biosciences). Then 5mL RPMI 1640 containing 5% FBS
was added to wash the stomacher bag and transferred to the same centrifuge
tube through the strainer. After the wash was added, the cell suspension was
centrifuged at 1,500 rpm for 5 minutes at 4˚C. The supernatant was discarded
and the cells were incubated with 5mL ACK lysis buffer (0.15 M NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA, pH=7.4) at room temperature to deplete erythrocytes.
After 5 minutes incubation, 10mL PBS w/o calcium and magnesium (Gibco) was
added to cease the lysis. 100μL of the cell suspension after lysis was
immediately diluted and counted, before the cells were centrifuged at 1,500 rpm
for 5 minutes. Then the cells were washed again with PBS w/o calcium and
magnesium before they were suspended in 5mL RPMI 1640 containing 5% FBS
to make the final suspension.
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2.3.1.2 Thymus
Thymus was isolated, weighed and placed in a 60mm culture dish (BD
Biosciences) immediately after the mouse was sacrificed. The isolated thymus
was then mechanically disrupted through a 100μm cell strainer into 10mL RPMI
1640 containing 5% FBS. The cell suspension was transferred into a 15mL
centrifuge tube (BD Biosciences). 5 mL RPMI 1640 containing 5% FBS was
added to wash the dish and strainer, and then transferred to the same centrifuge
tube. After the wash was added, the cell suspension was centrifuged at 1,500
rpm for 5 minutes at 4˚C. The cells were suspended in 5mL RPMI 1640
containing 5% FBS to make the final suspension.
2.3.1.3 Lymph nodes
Mesenteric lymph nodes were isolated and weighed immediately after a
mouse was sacrificed. 2-4 lymph nodes were used for making single cell
suspensions following the method that was described in chapter 2.2.1.2. The
cells were finally suspended in 2mL RPMI 1640 containing 5% FBS.
2.3.1.4 Blood
Blood was collected from mouse by abdominal arterial puncture. To
prevent coagulation, the needles were pre-rinsed with 0.5M EDTA (Sigma) and
the collected blood was immediately mixed with 20μl 0.5M EDTA in a 1.5mL EP
tubes. 300uL anti-clotted blood was added to 5mL ACK lysis buffer in a 50mL
centrifuge tube to remove red blood cells. 5 minutes after incubation, 45mL PBS
w/o calcium and magnesium was added to cease lysis and the cells were
immediately centrifuged at 1,500 rpm for 5 minutes at 4˚C. The pellet was
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resuspended with 1mL RPMI 1640 containing 5% FBS to make the final
suspension.
2.3.1.5 Bone marrow
Two femurs were removed immediately after a mouse was sacrificed.
After both ends of a femur were cut, 5 mL RPMI 1640 containing 5% FBS was
used to flush out the bone marrow cells into a 15mL centrifuge tube. Bone
marrow cells from two femurs of one mouse were pooled together and then
moved into a 50mL centrifuge tube through a 100μm cell strainer. The cells were
centrifuged at 1,500 rpm for 5 minutes at 4˚C and resuspended in 1mL RPMI
1640 containing 5% FBS to make the final suspension.
2.3.2 Cell counting
For splenocytes, 100μL cell suspension was diluted 10-fold with RPMI
1640 containing 5% FBS immediately after lysis and then counted using a
counting chamber. For thymocytes, 100μL final cell suspension was diluted 10fold, 20-fold or 50-fold with RPMI 1640 containing 5% FBS and then counted
using a counting chamber. For lymph node cells and whole blood cells, 10μL final
cell suspension was directly counted without dilution with a counting chamber.
The number of lymph node cells was normalized to cells per 2 lymph nodes. The
concentration of blood cells was shown as cells per mL blood. For bone marrow
cells, 10μL final cell suspension was 100-fold diluted with RPMI 1640 containing
5% FBS and then counted using a counting chamber.
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2.3.3 Surface marker antibody staining
The antibodies used in this project are listed in Table 1. For most assays
in this project, 5x105 cells were first incubated with 0.25μg anti-mouse
CD16/CD32 in 30μL FACS staining buffer (PBS w/o calcium and magnesium
containing 1% BSA) for 10 minutes at 4˚C to block Fc receptors. Then 20μL
FACS staining buffer containing fluorescent dye-labeled antibodies (0.125μg per
antibody) was added to make a final volume of 50μL and the cells were
incubated at 4˚C 30 minutes. After incubation, the cells were washed twice with
500μL FACS staining buffer. Finally the stained cells were suspended in 250μL
FACS staining buffer and analyzed with FACSCalibur or LSRII flow cytometer
(BD Biosciences). The generated data were analyzed with FlowJo software
(Treestar).
For TUNEL, BrdU or filipin staining assay, 1 million cells were stained with
0.25μg of antibody in 100μL staining buffers and washed with doubled volume of
buffers before subsequent staining. For ETP staining or bone marrow progenitor
analysis, 5~15 million cells were stained and washed with proportionally
increased volume of buffers and antibodies. The stained cells were suspended in
1~1.5mL FACS staining buffer before analysis.
2.3.4 TUNEL apoptosis detection assay
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) is
a widely used method for detecting DNA fragmentation which is an essential
marker for cell apoptosis [264, 265]. Briefly, 1 million cells were first stained with
antibodies recognizing surface antigens as described in chapter 2.2.3, followed
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by incubation with 100μL BD Cytofix/Cytoperm solution (BD Biosciences) for 20
minutes at room temperature. After washing twice with 1x BD Perm/Wash buffer
(BD Biosciences), the cells were incubated with 50μL TUNEL reaction mixture
(Roche) that was prepared following the manufacture instructions for 45 minutes
at 37˚C. Finally the cells were washed twice with FACS staining buffer,
suspended in 500μL FACS staining buffer and analyzed with flow cytometer.
2.3.5 BrdU incorporation detection
The BrdU incorporation was evaluated using a commercial BrdU kit (BD
bioscience) following instructions of the manufacture. Briefly, 1 million cells were
first stained with antibodies recognizing surface antigens as described in chapter
2.2.3, followed by incubation with 100μL BD Cytofix/Cytoperm solution for 20
minutes at room temperature. After washing twice with 1x BD Perm/Wash buffer,
the cells were incubated with 100μL BD Cytoperm Permeabilization Buffer Plus
for 10 minutes at room temperature and again washed twice with 1x BD
Perm/Wash buffer. After the wash, the cells were suspended in 100μL BD
Cytofix/Cytoperm solution and incubated for 5 minutes, before they were washed
twice with 1x BD Perm/Wash buffer. Later, the fixed cells were incubated with
100μL 300μg/mL DNase in PBS for 1 hour at 37˚C to expose the incorporated
BrdU. After the DNase was washed away with 1x BD Perm/Wash buffer, the cells
were stained with 1:50 APC-conjugated anti-BrdU antibodies in 50μL 1x BD
Perm/Wash buffer. Finally, the cells were washed with FACS staining buffer
twice and suspended in 250μL FACS staining buffer before analysis.
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2.3.6 Filipin staining
Filipin is a highly fluorescent compound that specifically binds cholesterol.
Thus it can be used as a probe to evaluate the level of cholesterols [191, 266,
267]. One million thymocytes of mice were first stained with surface markers and
then incubated with 100μL BD Cytofix/Cytoperm solution (BD Biosciences) for 20
minutes at room temperature. After washing twice with 1x BD Perm/Wash buffer
(BD Biosciences), the cells were incubated with 100μL 100μg/mL filipin (Sigma)
in 1x BD Perm/Wash buffer for 1 hour at 37˚C. Finally the cells were washed
twice, suspended in 100μL PBS and analyzed with flow cytometer.
2.4 T cell receptor excision circles detection
T cell receptor excision circles (TRECs) are circular DNA molecules
generated during TCR rearrangements which lack the ability to replicate. These
molecules were diluted during T cell proliferation and thus nicely correlated with
T cell production [90, 268, 269]. To detect TRECs in T cells, splenocytes of mice
were stained with surface antibodies as described in chapter 2.2.3. Then CD4+
and CD8+ splenocytes were sorted with an iCyt Synergy sorter system (Sony).
The cell lysate was prepared by incubating 10,000 cells/μL isolated cells with
0.4μg/μL proteinase K (QIAGEN) at 55˚C for one hour, followed by inactivating
proteinase at 95˚C for 15 minutes. The lysate from 50,000 cells (5μL) was added
to a quantitative PCR (qPCR) reaction.
The qPCR was performed using a LightCycler 480 Instrument (Roche).
The forward primer to amplifying TRECs was 5’-CAT-TGC-CTT-TGA-ACC-AAGCTG-3’ and the reverse primer was 5’-TTA-TGC-ACA-GGG-TGC-AGG-TG-3’.
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The probe was 5’-FAM-CAG-GGC-AGG-TTT-TTG-TAA-AGG-TGC-TCA-CTTBlack hole Quencher-1-3’ (synthesized by Integrated DNA Technologies). The
reaction system was modified from previous report [90] and contained 12.5μL
LightCycler 480 Probes Master (Roche), 1μL 0.5μM forward primer, 1μL 0.5μM
reverse primer, 1μL 12.5μM probe, 4.5μ H2O and 5μL templates. The qPCR
program was set as: step 1: 10 minutes at 95°C; step 2: 15 seconds at 95°C, 1
minute at 60°C, single data collection, 45 cycles; step 3: 37°C, hold.
The standard curves for murine TRECs were generated by using standard
mouse TRECs plasmids, which were a generous gift from Dr. Gregory D.
Sempowski, Duke University Medical Center [90]. For each real-time PCR assay,
stock dilutions of 107, 106, 105, 104, 103 and 102 plasmids per 5uL were run in
triplicate to generate standard curves. TREC frequency of isolated cells was
determined in triplicate and expressed as the number of TRECs per 100 cells.
The total number of TRECs of a given population was calculated by multiplying
the TREC frequency by the number of that population.
2.5 CFSE labeling
CFSE is a widely used fluorescent cell staining dye for in vivo cell tracing
[270]. In this project, we used CFSE-labeled bone marrow cells in the short-term
homing assay (described in 2.2.3). We labeled bone marrow cells with CFSE
using a commercial kit (Molecular Probes). Briefly, bone marrow cells were first
suspended in PBS containing 0.1% BSA at a concentration of 20 million cells per
mL. Then 2μL 5mM CFSE stock solution per mL of cells was added to make a
final CFSE concentration of 10μM, followed by incubation with cells at 37°C for
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10 minutes. The staining was quenched by adding 5 volumes of ice-cold PBS
and incubation on ice for 5 minutes. After washing cells three times with PBS, the
cells were suspended in PBS at the concentration of 20 million cells per 100μL
before being injected into mice.
2.6 in vitro T cell activation
Splenocytes or lymph node cells from mice were plated at a concentration
of 4 x 106 cells per mL in a 96-well plate and cultured in RPMI 1640 medium
supplemented with 10% FBS, 5 mM L-glutamine (Gibco), 100 units/mL penicillin,
100 μg/mL streptomycin, and 50μM 2-mercaptoethanol (2-ME). For anti-CD3
stimulation, the plates were incubated with 100μL anti-CD3 (eBioscience) in PBS
at indicated concentrations overnight and washed twice with 100 μL PBS before
use. For proliferation assay, 5μg/mL pre-bound anti-CD3 were used to stimulate
T cells and 10 μM BrdU was added to track new born cells. After 96 hours
incubation at 37°C, BrdU incorporation in T cells was analyzed by FACS. For
activation assays, cells were stimulated with indicated concentrations of prebound anti-CD3 and soluble anti-CD28 (eBioscience). Forty-eight hours later,
CD69 expression in T cells was evaluated.
2.7 Plasma cholesterol determination
Fresh anti-coagulated blood was drawn by tail bleeding or from abdominal
aorta from mice and used to determine plasma cholesterol concentrations.
Quantitative determination of plasma total cholesterol was performed with
enzymatic colorimetric method following the instruction from manufacturer (Wako
Pure Chemical Industries, Ltd).
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2.8 Western blot
The thymi from 5-week-old mice were first lysed with cell lysis buffer (cell
signaling) in the presence of proteinase inhibitor (Sigma), before being
centrifuged at 12,000 rpm for 15 minutes at 4°C. The protein concentration in the
supernatant was determined by Lowry protein assay [271] with a commercial kit
(Biorad). Then, 100μg (by protein) cell lysate was loaded and resolved in a
12.5% polyacrylamide gel. After the gel electrophoresis, the protein in the gel
was electrically transferred to a polyvinylidene fluoride (PVDF) membrane, which
was then blocked with 5% milk in Tris-Buffered Saline with Tween 20 (TBST,
50mM Tris, 150mM NaCl, 0.05% Tween 20, pH=7.6) at room temperature for 1
hour and incubated with 1:10000 anti-caspase 1 (4B4, a gift from Dr. Vishva
Dixit, Genentech) in 5% milk/TBST at room temperature for 1 hour. After washing
for three times with 0.25% milk/TTBS, the membrane was incubated with 1:1000
peroxidase-conjugated anti-Rat IgG in 0.25% milk/TTBS for 1 hour at room
temperature. After washing three times with 0.25 milk/TTBS, the membrane was
incubated with peroxidase substrates (Thermo Scientific) for 5 minutes before the
chemiluminescence was detected.
Then the membrane was stripped with stripping buffer (Thermo Scientific)
and blotted with 1:500 anti-β-tublin (E7-c, Developmental Studies Hybridoma
Bank). After washing, the membrane was incubated with 1:5000 peroxidaseconjugated anti-mouse IgG and detected as described upon.
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2.9 Statistic analysis
In this dissertation, data were all shown as mean ± standard error.
Comparison of two groups was by 2-tailed Student’s t-test. P values for survival
curves were determined from the Kaplan-Meier survival curves by use of the
Log-Rank test utilizing SAS software. Means were considered different at p <
0.05.

54

Figure 2.1 Genotyping for SR-BI alleles.
PCR system for SR-BI genotyping was set up as described in 2.1.5.3. Fifteen
microliter amplified DNA product was resolved in a 1.5% agarose gel under 100
volts for 30 minutes.
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Figure 2.2 Genotyping for Rag-1 alleles.
PCR system for Rag-1 genotyping was set up as described in 2.1.5.4. Ten
microliter amplified DNA product was resolved in a 2.0% agarose gel under 100
volts for 30 minutes.
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Figure 2.3 Genotyping for LDLR alleles.
PCR system for LDLR genotyping was set up as described in 2.1.5.5. Ten
microliter amplified DNA product was resolved in a 2.5% agarose gel under 100
volts for 30 minutes.
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Table 2.1 Antibodies used for flow cytometry.
Antigen
BrdU

Clone
RA36B2

Format
APC

Source
BD Biosciences

FITC

Biolegend

CD2

RM2.5

FITC

Biolegend

CD3ε

17A2

FITC

BD Biosciences

CD4

GK1.5

APC

Biolegend

CD4

GK1.5

FITC

Biolegend

CD4

GK1.5

PE

Biolegend

CD8α

53.67

FITC

Biolegend

CD8α

53.67

PE-cy5

BD Biosciences

CD8β

53.58

FITC

Biolegend

CD11b

M1/70

FITC

Biolegend

CD11b

M1/70

CD11c
CD16/
CD32

n148

PerCPcy5.5
FITC

93

CD19

B220

Note
Proliferation marker
Lineage marker for ETP and bone
marrow progenitor staining
Lineage marker for bone marrow
progenitor staining
Lineage marker for ETP and bone
marrow progenitor staining
Thymocyte and peripheral T cell
subset staining
Lineage marker for bone marrow
progenitor staining
Thymocyte and peripheral T cell
subset staining
Lineage marker for ETP and bone
marrow progenitor staining;
Thymocyte and peripheral T cell
subset staining
Thymocyte and peripheral T cell
subset staining
Lineage marker for ETP staining
Lineage marker for ETP and bone
marrow progenitor staining

BD Biosciences

Thymic macrophage staining

Biolegend

Lineage marker for ETP staining

Purified

BD Biosciences

Fc blocking

6D5

FITC

Biolegend

CD25

PL61

APC

Biolegend

CD44

1M7

PE-cy5

Biolegend

CD45

30-F11 APC

BD Biosciences

CD45.1

A20

PE-cy7

Biolegend

CD45.2

104

APCcy7

Biolegend

PE-cy7

Biolegend

PE

BD Biosciences

APC

Biolegend

CD62L
CD69
CD135

MEL14
H1.2F
3
A2F10
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Lineage marker for ETP and bone
marrow progenitor staining
Thymocyte subset staining
Thymocyte and peripheral T cell
subset staining
For blood lymphocyte staining
Bone marrow transplantation and
thymic homing assay
Bone marrow transplantation and
thymic homing assay
Thymocyte and peripheral T cell
subset staining
Thymocyte subset staining;
activation marker
Bone marrow progenitor staining

Table 2.1 Antibodies used for flow cytometry (continued).
Antigen
CD135

Clone
A2F10

Format
APC

Source
Biolegend

cKit

2B8

PE

Biolegend

F4/80

BM8
RB68C5
A7R34

PE

eBioscience
Biolegend

APCcy7

Biolegend

NK1.1

PK136

FITC

Biolegend

Sca-1
TCR-β
TCRγ/δ

D7
H57

PE-cy7
FITC

Biolegend
Biolegend

Lineage marker for ETP and bone
marrow progenitor staining
Bone marrow progenitor staining
Lineage marker for ETP staining

GL3

FITC

Biolegend

Lineage marker for ETP staining

Ter119

Ter119 FITC

Biolegend

Lineage marker for ETP and bone
marrow progenitor staining

GR-1
IL-7Rα

FITC

Note
Bone marrow progenitor staining
Bone marrow progenitor and ETP
staining
Thymic macrophage staining
Lineage marker for ETP and bone
marrow progenitor staining
Bone marrow progenitor staining

Copyright © Zhong Zheng 2014

59

Chapter 3

SR-BI is required for maintaining normal thymopoiesis and

peripheral T cell homeostasis
3.1 Introduction
Our group previously reported that SR-BI deficiency results in impaired
lymphocyte homeostasis in mice [134]. The key features of the impaired
lymphocyte homeostasis in SR-BI-deficient mice include lymphocyte expansion,
lymphocyte hyperactivation, lymphocyte hyperproliferation and a decrease in T
cell to B cell ratio. Later, we identified that the HDL from SR-BI-/- mice is
dysfunctional in inhibiting stimuli-induced proliferation of both T cells and B cell,
which is responsible for the lymphocyte expansion, hyperactivation and
hyperproliferation in the deficient animal [134]. However, the dysfunctional HDL
is not likely responsible for the reduced percentage of T cells, suggesting SR-BI
probably plays additional roles in preventing lymphocyte imbalance.
Several pieces of evidence have suggested an additional role of SR-BI in
adaptive immunity in maintaining normal thymopoiesis. In addition to the
decrease in T cell/B cell ratio, SR-BI-null mice display several other phenotypes
potentially resulting from reduced T cell productions. First, SR-BI-deficient mice
show a reduced percentage of naïve populations and increased portion of
memory population in T cells [134], which is commonly seen in mice whose T cell
production is decreased [43, 44]. Second, T cells from SR-BI-deficient mice
display reduced cytokine production in response to stimuli in vitro [134], which
might be the consequence of the inadequate refreshment of the T cell pool by
newly generated T cells that is known to cause T cell senescence and impaired T
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cell functions to stimuli [62-64]. Third, aged SR-BI-deficient mice have
autoimmune problems [134], which might also be contributed by decreased
thymopoiesis that is known to cause accumulation of autoimmune T cells in the
periphery [50-53]. These observations implied that SR-BI might modulate T cell
development.
We hypothesized that SR-BI deficiency impairs thymopoiesis, which
contributes to the lymphocyte imbalance in SR-BI-null mice. To test this
hypothesis, in this chapter, we first analyzed thymus weight and thymic cellularity
of SR-BI-deficient mice at different ages and observed that SR-BI deficiency
causes reduced thymus size in mice. Next, we evaluated T cell production by
detecting TRECs in mice and found that SR-BI deficiency causes declined T cell
production. The reduced thymus size and declined T cell production of SR-BI-null
mice together indicate that SR-BI deficiency impairs thymopoiesis in mice. By
assessing the peripheral T cell homeostasis of mice, we found that the decline of
T cell production in the deficient mice leads to narrowed naïve T cell pool in the
periphery and compromised T cell functions at young ages. Results from these
studies indicate that SR-BI is required in maintaining normal thymopoiesis and
peripheral T cell homeostasis.
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3.2 Results
3.2.1 SR-BI deficiency leads to reduced thymus weight in mice
To understand if SR-BI plays a role in modulating thymus size, we first
evaluated thymus weight of SR-BI-/- mice after puberty (around 5 weeks), when
thymus size declines as age increases [87, 272]. As shown in Figure 3.1A and
3.1B, though an age-related decrease in thymus mass was observed in both
groups, SR-BI-/- mice display significantly lower thymus weight than age-matched
SR-BI+/+ controls until 32 weeks. In older ages (>32 weeks), the reduction in
thymus weight of SR-BI-/- mice was not observed, as thymus weight of both
groups has declined to a low level. This group of data indicates that SR-BI
deficiency causes a reduction in thymus weight in mice.
3.2.2 SR-BI deficiency results in decreased thymic cellularity in mice
We also assessed thymocyte number of SR-BI-/- mice after puberty. In line
with the lower thymus weight, the deficient mice exhibit markedly smaller thymic
cellularity than with age-matched controls (Figure 3.2A and 3.2B). Notably, the
reduction in thymic cellularity could still be observed when the SR-BI-/- mice were
over 40 weeks. This group of data show that SR-BI deficiency results in reduced
thymic cellularity in mice.
3.2.3 SR-BI modulates thymus size in a gender-independent manner
It is well documented that in both humans and mice, females have larger
thymic size and higher-grade thymopoiesis than males, indicating gender is an
essential factor influencing the thymus [272, 273]. Thus, we next analyzed if SRBI influences thymus size in a gender-dependent manner. We observed that in
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both male and female group, SR-BI-/- mice exhibit significantly reduced thymus
weight in early ages (<16 weeks for female and <40 weeks for male) and
remarkably decreased thymocyte counts compared with their SR-BI+/+
counterparts (Figure 3.3). These observations reveal that the effect of SR-BI on
thymus size is not gender-dependent.
3.2.4 SR-BI does not affect thymus size before puberty
We then asked when SR-BI deficiency begins to affect thymus size in
mice. To answer this question, we examined thymus weight and thymic cellularity
in mice before puberty (1 week of age) and during puberty (5 weeks of age).
Consistent with former observations, 5-week-old SR-BI-/- mice display significant
reductions in both thymus weight and thymocyte counts compared with 5-weekold SR-BI+/+ mice (Figure 3.4A and 3.4B). However, neither thymus weight nor
thymic cellularity of 1-week-old SR-BI-/- mice is significantly lower than those of
their SR-BI+/+ littermates (Figure 3.4A and 3.4B), indicating that SR-BI does not
affect thymus size before puberty.
3.2.5 SR-BI deficiency causes a decline in thymic T cell output
T cell production from the thymus is usually correlated with thymus size
[274]. Thus, we next hypothesized that the SR-BI deficiency induces reductions
in thymic T cell export associated with the decrease of thymus size. To test this,
we determined TRECs in CD4+ and CD8+ splenocytes isolated from mice. As
expected, the frequency of TRECs in both CD4+ and CD8+ cells from SR-BI-/mice is lower (Figure 3.5A and 3.5B), indicating that the frequency of newly
generated T cells is decreased by SR-BI deficiency. More importantly, the
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absolute numbers of TRECs are decreased by 26% and 22% respectively in
CD4+ and CD8+ splenocytes of SR-BI-/- mice (Figure 2.5C and 2.5D), indicating
that the loss of SR-BI also reduces the number of RTEs. This group of data
indicate that SR-BI deficiency reduces thymic T cell output in addition to lowering
thymus size.
3.2.6 SR-BI deficiency leads to narrowed naïve T cell pool in the periphery
Continuous T cell output from the thymus is essential in maintaining
peripheral T cell homeostasis. Inadequate T cell production narrows naïve T cell
pool and compromises T cell functions in the periphery [62, 92]. Though 20week-old SR-BI-/- mice show reduced percentage of naïve population in T cells,
their naïve T cell numbers are not decreased [134], which may result from
increased T cell proliferation induced by dysfunctional HDL. To further investigate
how SR-BI deficiency-impaired thymopoiesis affects peripheral T cell
homeostasis, we evaluated CD62L and CD44 expression in T cells from lymph
nodes, spleen and blood in younger mice.
We found that in lymph nodes from 5-week-old SR-BI-/- mice, the
percentages of the naïve (CD62LhiCD44-) cells in CD4+ and CD8+ population are
all significantly reduced compared with SR-BI+/+ controls, while the portion of
memory T cells (CD62LhiCD44+, central memory T cells and CD62LlowCD44+,
effector memory T cells) is elevated, in line with the observations in 20-week-old
mice (Figure 3.6A-3.6D). However, the numbers of lymph node naïve cells in
CD4+ and CD8+ population are also reduced by 34% and 36% respectively in the
5-week-old deficient mice, indicating that their naïve T cell pool size is narrowed
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(Figure 3.6F and 3.6G). Shrinkage in the naïve T cell pool of SR-BI-/- lymph
nodes is not due to heightened T cell activation, since the total number of
memory T cells is not increased (Figure 3.6 F and 3.6G). The decrease in the
number of naïve T cells results in a marginal reduction in total T cell numbers in
lymph nodes from 5-week-old SR-BI-/- mice (Figure 3.6E).
The SR-BI deficiency-induced reductions in lymph node naïve T cell
counts were also observed in 13-week-old mice. Though compared with 5-weekold group, the percentage of naïve cells in T cells in both SR-BI+/+ and SR-BI-/mice is declined in 13-week-old group (Figure 3.7A and 3.7B, in comparison with
Figure 3.6B and 3.6D), the T cells from SR-BI-/- lymph nodes display lower
portion of naïve subsets than those from SR-BI+/+ counterparts (Figure 3.7A and
3.7B). Meanwhile, the total numbers of naïve cells in CD4+ and CD8+ population
are reduced by 50% in lymph nodes from 13-week-old SR-BI-/- mice (Figure 3.7C
and 3.7D). These findings from 5-week-old and 13-week-old mice together
indicate that the absence of SR-BI narrows the naïve T cell pool in lymph nodes.
We also assessed the naïve T cell pool in spleens and blood of 5-weekold SR-BI-/- mice. Consistent with the observations from lymph nodes, SR-BI-/mice show remarkable decreases in naïve T cell percentage (Figure 3.8A-3.8D)
and marginal reductions in naïve T cell number in spleen (Figure 3.8E and 3.8F).
Importantly, a dramatic decline in the blood naïve T cell concentrations was
detected in SR-BI-/- mice compared with SR-BI+/+ mice (Figure 3.8G). These
observations support our conclusion that SR-BI deficiency-impaired thymopoiesis
result in a narrowed naïve T cell pool in mice.
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3.2.7 SR-BI deficiency leads to increased proliferation of naïve T cells
Naïve T cells rarely proliferate under normal conditions. However, reduced
naïve T cells in the periphery can increase naïve T cells proliferation as a
compensatory mechanism to maintain the relative steady naïve T cell pool size
[17]. Thus, we hypothesized that SR-BI deficiency-reduced T cell output results
in an increase in the proliferation of naïve T cells. To test this hypothesis, we
injected BrdU to mice and analyzed BrdU incorporation in naïve CD4+ cells. As
expected, SR-BI-/- mice show 40% and 30% decreases in the BrdU+ percentage
of naïve CD4+ cells in spleen (Figure 3.9A and Figure 3.9B) and lymph nodes
(Figure 3.9C and Figure 3.9D) compared with SR-BI+/+ mice, though the
decrease does not reach statistically significance in lymph nodes (Figure 3.9A
and Figure 3.9B). These observations further support that SR-BI deficiency
reduced T cell production and impaired peripheral T cell homeostasis.
3.2.8 SR-BI deficiency causes compromised T cell function
Reduced T cell production is also known to compromise T cell functions in
the periphery [62, 92]. Thus, we determined if the declined T cell output in SR-BI/-

mice results in impaired T cell functions. For this purpose, we activated

splenocytes from mice with anti-CD3 in vitro, and detected the proliferation of T
cells using BrdU. As expected, we found significantly lower BrdU+ percentage in
CD4+ (Figure 3.10A and 3.10B) and CD8+ (Figure 3.10C and 3.10D) cells in SRBI-/- group than SR-BI+/+ controls. Moreover, the counts of newborn (BrdU+) CD4+
and CD8+ cells are dramatically (>70%) decreased in SR-BI-/- group (Figure
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3.10E and 3.10F), indicating that T cells from SR-BI-/- mice have impaired stimuliinduced proliferation of T cells.
To further confirm that the SR-BI deficiency causes T cell dysfunctions in
response to stimuli, we assessed the activation status of SR-BI-/- T cells after
incubation with TCR ligand by detecting the expression of the T cell activation
marker CD69 (Figure 3.11). Forty-eight hours after cell culture, though in the
absence of stimuli, T cells from SR-BI+/+ and SR-BI-/- mice show low and
comparable levels of CD69 expression, in the presence of stimuli SR-BI-/- T cells
show markedly reduced level of CD69 expression in comparison with SR-BI+/+ T
cells (Figure 3.11 A-D). This group of data reveals that T cells from SR-BI-/- mice
have compromised stimuli-induced activation.
Previously, we also reported that SR-BI-/- T cells display reduced IL-4
secretion in response to TCR ligand engagement [134], demonstrating SR-BI
deficiency also renders T cells dysfunctional in stimuli-induced cytokine
secretion. Altogether, this group of data elucidates that SR-BI deficiency causes
compromised T cell functions associated with decreased T cell production and
the impaired peripheral T cell homeostasis.
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3.3 Summary
In this chapter, we tested our hypothesis that SR-BI deficiency caused
impaired thymopoiesis, which contributed to the lymphocyte imbalance in SR-BInull mice. By assessing thymus weight and thymic cellularity of SR-BI-/- mice
(Figure 3.1 and 3.2), we found that absence of SR-BI in mice causes a reduction
in thymus size. Notably, the adverse effect of SR-BI deficiency on thymus size is
not gender-dependent (Figure 3.3) and initiates around puberty (Figure 3.4). By
detecting TRECs in isolated T cells from mice, we revealed that SR-BI deficiency
decreases T cell output (Figure 3.5). Reduced thymus size and thymic output
together lead us to conclude that SR-BI deficiency impaired thymopoiesis in
mice. By examining the T cell homeostasis in mice at young ages, we observed
that SR-BI-null mice display a narrowed naïve T cell pool size (Figure 3.6, 3.7
and 3.8) and increased naïve T cell proliferation (Figure 3.9). These observations
indicate that SR-BI deficiency leads to impaired T cell homeostasis in the
periphery. Finally, by evaluating T cell responses to stimuli in vitro, we found that
SR-BI deficiency also compromises T cell functions (Figure 3.10 and 3.11).
Altogether, in this chapter, we identify SR-BI as a novel modulator in
thymopoiesis. Our data clearly indicate that SR-BI is required in maintaining
normal thymopoiesis and optimal peripheral T cell homeostasis in mice.
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Figure 3.1 SR-BI deficiency reduces thymus weight in mice.
The thymi of mice without any treatment were isolated and weighed. A) The agerelated changes in thymus weight of SR-BI+/+ (n=322) and SR-BI-/- (n=221) mice
after puberty are displayed. B) The weight of SR-BI-/- (n=221) thymi is grouped by
age and compared with age-matched SR-BI+/+ (n=322) controls. *, p<0.05; **,
p<0.01; ***, p<0.001.
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Figure 3.2 SR-BI deficiency decreases thymic cellularity in mice.
The thymi of mice were mechanically disrupted through 100μm cell strainers and
re-suspended with 5mL medium. The thymocyte suspension was then diluted
and counted using a counting chamber. The total thymocyte number in the 5mL
suspension was regarded as the thymic cellularity of mice. A) The age-related
changes in the thymic cellularity of SR-BI+/+ (n=145) and SR-BI-/- (n=92) mice
after puberty are shown. B) The thymic cellularity of SR-BI-/- (n=92) mice is
grouped by age and compared with age-matched SR-BI+/+ (n=145) controls. *,
p<0.05; ***, p<0.001.
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Figure 3.3 SR-BI deficiency reduces thymus size in both males and
females.
A)-D) Reduced thymus weight was detected in both female (A and B) and male
(C and D) SR-BI-/- mice compared with SR-BI+/+ controls. E)-H) Decreased thymic
cellularity was observed in both female (E and F) and male (G and H) SR-BI-/mice compared with SR-BI+/+ controls. *, p<0.05; **, p<0.01; ***, p<0.001.
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Figure 3.4 SR-BI deficiency does not decrease thymus size before puberty.
A) 5-week-old but not 1-week-old SR-BI-/- mice exhibit lower thymus weight than
age-matched SR-BI+/+ mice. n=5-8 per group. B) 5-week-old but not 1-week-old
SR-BI-/- mice display reduced thymocyte counts compared with age-matched SRBI+/+ mice. n=5-8 per group. **, p<0.01.

73

Figure 3.5 SR-BI deficiency reduces T cell output from thymus.
CD4+ and CD8+ splenocytes were sorted from 13-week-old SR-BI+/+ and SR-BI-/mouse by flow cytometry and then lysed with proteinase K. The lysates from
50,000 cells were used for TREC detection with quantitative PCR. A)-B) The
frequency of TRECs is showed as TREC numbers per 100 CD4+ or CD8+ cells.
C)-D) The total number of TRECs of a given population was calculated by
multiplying the TREC frequency by the number of cells. n=3 per group with
triplicate measurements. *, p<0.05.
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Figure 3.6 SR-BI deficiency reduces naïve T cell pool in lymph nodes of 5week-old mice.
Mesenteric lymph nodes from 5-week-old SR-BI+/+ and SR-BI-/- mice were
mechanically disrupted through 100μm cell strainers and stained with a panel of
fluorescent-labeled antibody. Cells were then analyzed by flow cytometry. A)-D)
Based on expression of CD62L and CD44, three major cell subtypes of CD4+ (A
and B) or CD8+ (C and D) cells were gated: naïve cells (CD62LhiCD44-), central
memory cells (CD62LhiCD44+) and effector memory cells (CD62LloCD44+). E)
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The total number of CD4+ or CD8+ cells of a given mouse was calculated by
multiplying its CD4+ or CD8+ percentage in total viable lymph node cells by the
number of lymph node cells. F)-G) The total number of a CD4+ or CD8+ subtype
in a given mouse was calculated by multiplying its percentage in CD4+ or CD8+
cells by the CD4+ or CD8+ cell numbers. n=5-6 per group. *, p<0.05; ***, p<0.001.
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Figure 3.7 SR-BI deficiency reduces naïve T cell pool in lymph nodes of
13-week-old mice.
Mesenteric lymph nodes from 13-week-old SR-BI+/+ and SR-BI-/- mice were
mechanically disrupted through 100μm cell strainers and stained with a panel of
fluorescence-labeled antibody. Cells were then analyzed by flow cytometry. A)B) Based on expression of CD62L and CD44, three major cell subtypes in CD4+
(A) or CD8+ (B) cells were gated: naïve cells (CD62LhiCD44-), central memory
cells (CD62LhiCD44+) and effector memory cells (CD62LloCD44+). C)-D) The total
number of a CD4+ or CD8+ subtype of a given mouse was calculated by
multiplying its percentage in CD4+ or CD8+ cells by the CD4+ or CD8+ cell
numbers. n=5 per group. *, p<0.05.
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Figure 3.8 SR-BI deficiency reduces naïve T cell pool in spleen and blood
of 5-week-old mice.
A)-D) Spleens from SR-BI+/+ and SR-BI-/- mice were disrupted with a stomacher,
incubated with ACK lysis buffer to deplete erythrocytes and stained with a panel
of fluorescent-labeled antibody. Cells were the analyzed by flow cytometry.
Based on expression of CD62L and CD44, three major cell subtypes in CD4+ (AB) and CD8+ (C-D) cells were gated: naïve cells (CD62LhiCD44-), central memory
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cells (CD62LhiCD44+) and effector memory cells (CD62LloCD44+). E)-F) The total
number of a CD4+ or CD8+ subtype of a given mouse was calculated by
multiplying its percentage in CD4+ or CD8+ cells by the splenic CD4+ or CD8+ cell
numbers. n=5-6 per group. G) anti-clotted blood from SR-BI+/+ and SR-BI-/- mice
was first incubated with ACK lysis buffer to remove erythrocytes, stained with a
panel of fluorescent-labeled antibody and analyzed with a flow cytometer. The
naïve cells were defined as CD62LhiCD44- population in CD4+ or CD8+ cells. The
concentration of naïve cells was calculated by multiplying the percentage of
naïve T cells CD45+ blood cells by the CD45+ cell concentration of the mouse.
n=5-6 per group. *, p<0.05; **, p<0.01.
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Figure 3.9 SR-BI deficiency increases naïve T cell proliferation.
Five-week-old SR-BI+/+ and SR-BI-/- mice were given two i.p. injections (spaced
24 hours apart) of 1mg BrdU in 1mL sterile PBS. Forty-eight hours after the first
injection, mice were sacrificed. A)-B) BrdU incorporation in naïve CD4+ T cells
(CD4+CD62LhiCD44-) from spleens of mice was analyzed. n=7-8 per group. C)D) BrdU incorporation in naïve CD4+ T cells (CD4+CD62LhiCD44-) from lymph
nodes of mice was analyzed. n=5 per group. *, p<0.05.
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Figure 3.10 SR-BI deficiency impairs stimuli-induced proliferation of T
cells.
Eight hundred thousand splenocytes from SR-BI+/+ or SR-BI-/- mice (8-12 weeks)
were incubated with 20μM BrdU in the presence of 5μg/mL pre-bound anti-CD3
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for four days. A)-D) The incorporation of BrdU in cultured CD4+ (A and B) and
CD8+ (C and D) T cells was analyzed. E)-F) The total number of BrdU+CD4+ or
BrdU+CD8+ populations were calculated by multiplying its percentage in cultured
cells by total cell numbers in cell cultures after 4-day incubation. n=14 per group.
*, p<0.05; ***, p<0.001.
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Figure 3.11 SR-BI deficiency impairs stimuli-induced activation of T cells.
Two hundred thousand lymph node cells from SR-BI+/+ or SR-BI-/- mice (8 weeks)
were incubated with 20μM BrdU in presence of indicated concentrations of prebound anti-CD3 and soluble anti-CD28. A)-D) After 48-hour incubation, the level
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of CD69 expression in CD4+ (A and B) and CD8+ (C and D) cells was detected.
MFI: mean fluorescence intensity. n=3 per group. *, p<0.05; **, p<0.01.
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Chapter 4

SR-BI is required in maintaining normal bone marrow

progenitor thymic homing and thymic regeneration
4.1 Introduction
T lineage cells in the thymus undergo an established program in which
they develop from bone marrow-derived progenitors to mature naïve T cells. The
key events in thymopoiesis include the entry of bone marrow progenitors in
thymus; β-selection and generation of DP thymocytes; positive and negative
selections; generation and maturation of SP thymocytes and the export of mature
T cells from the thymus. Based on surface marker expression, thymocytes in
different developing stages can be distinguished. The percentage of thymocyte
subsets under normal conditions remains relatively stable. Alterations in the
percentage of one or more thymocyte subset are seen as indicators of changes
in T cell development [33, 34, 40].
Our data in chapter 3 indicates that SR-BI is a novel player in
thymopoiesis as SR-BI deficiency causes reduced thymus size and decreased
thymic output. However, the underlying mechanism for this is not understood. To
investigate the mechanism by which SR-BI modulates thymopoiesis, in this
chapter we analyzed thymocyte subtypes in SR-BI-deficient mice at young ages
in an effort to understand which steps in thymopoiesis are affected by SR-BI. We
found that the intrathymic T cell developmental program is intact in SR-BI-/- mice,
as no alterations in the percentage of major thymocyte subsets was observed in
the deficient mice. Interestingly, we found that SR-BI-null mice display a
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significant reduction in the percentage of ETPs, suggesting that SR-BI deficiency
reduces progenitor thymic entry in mice.
Changes in the ETP population of SR-BI-null mice led us to hypothesize
that SR-BI deficiency impairs thymopoiesis by affecting bone marrow-derived
progenitors upstream of ETPs. Starting from the HSCs in bone marrow, T lineage
progenitors experience two major developmental events before giving rise to
downstream cells in the thymus [77]. The first is the lymphoid progenitor
development in bone marrow, in which progenitors develop from HSCs to LMPPs
and CLPs to gain the ability of entering thymus. The second is the bone marrow
progenitor thymic homing, in which progenitors move out of bone marrow and
migrate to the thymus via the circulation. Reduced progenitor entry into the
thymus has been shown to decrease the portion of ETPs and lead to thymic
hypocellularity [83, 84]. Thus, to test our hypothesis, we evaluated bone marrow
progenitor development and progenitor thymic homing in SR-BI-/- mice. We found
that the absence of SR-BI does not affect lymphoid progenitor development in
bone marrow, but impairs progenitor thymic homing, demonstrating that SR-BI
deficiency causes impaired thymopoiesis in mice by inducing reduced bone
marrow progenitor settlement in the thymus.
Acute thymus involution can be induced by several factors and the thymic
recovery is slow [68, 275]. As SR-BI is required in maintaining normal thymus
size and function, we also tested whether SR-BI plays a role in modulating
thymic recovery after thymocyte depletion. Thymus regeneration in early stages
depends on intrathymic precursors [276] and in the long term requires the
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migration of bone marrow progenitors [277]. Due to the decreased portion of
ETPs and impaired thymic homing of SR-BI-/- mice, we hypothesized that SR-BI
deficiency impairs thymus regeneration after thymocyte depletion. To test this,
we induced thymocyte depletion with sublethal irradiation in mice and evaluated
subsequent thymic recovery. We observed SR-BI-null mice display delayed
thymic regeneration after irradiation.
Taken together, this data revealed that SR-BI deficiency impairs
thymopoiesis by decreasing progenitor thymic homing. Also, our results indicate
that SR-BI deficiency delays thymic recovery after thymocyte depletion.
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4.2 Results
4.2.1 SR-BI deficiency does not alter CD4/CD8 profile in the thymus
To investigate the mechanism by which SR-BI modulates thymopoiesis,
we initially stained thymocytes from 5-week-old SR-BI+/+ and SR-BI-/- with antiCD4 and anti-CD8. Based on the expression of these two markers, thymocytes
can be divided to DN, DP, 4SP and 8SP populations. We chose mice at 5 weeks
because at this age thymocyte number peaks and the reduction of thymic
cellularity in SR-BI-/- mice is significant. We observed a normal CD4/CD8 profile
in the SR-BI-/- thymi compared with the SR-BI+/+ counterparts (Figure 4.1A and
4.1B). The number of each population is reduced coordinately with the total
thymocyte number in the deficient mice (Figure 4.1 C). These findings are
consistent with our former observations in 6-week-old and 25-week-old mice
[134].
4.2.2 SR-BI deficiency does not change DN1-4 profile in the thymus
As a step further, we evaluated the DN1-4 profile of mice. We divided the
DN population into DN1, DN2, DN3 and DN4 cells based on the expression of
CD25 and CD44. We did not detect any difference in the percentage of the four
DN subsets in the deficient mice (Figure 4.2A and 4.2B), indicating SR-BI
deficiency does not affect the DN1-4 profile. Similarly, the numbers of all DN
subtypes are decreased due to the decline in total thymocyte numbers (Figure
4.2C).
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4.2.3 SR-BI deficiency does not affect selection processes in thymopoiesis
We evaluated if SR-BI deficiency affects selection processes, i.e. βselection, positive selection and negative selection in mice. To determine if SR-BI
deficiency influences β-selection, we evaluated TCR-β expression in DN cells.
SR-BI-/- show comparable TCR-β expression in DN cells with SR-BI+/+ mice
(Figure 4.3A), which together with the observation that the percentages of DN
subsets are unaltered in SR-BI-/- mice indicate that loss of SR-BI does not cause
any defect in β-selection.
We next assessed if SR-BI modulates selections in DP stage by
distinguishing the pre- and postselection DP thymocytes using expression of
CD69 and TCR-β [278]. Both SR-BI-/- and SR-BI+/+ mice exhibit ~10%
CD69+TCR-β+ (postselection) cells in the DP population (Figure 4.3B and 4.3C).
Meanwhile, the TCR-β expression in 4SP and 8SP population is also identical in
SR-BI-/- and SR-BI+/+ thymi (Figure 4.3D and 4.3E). These observations indicate
that SR-BI deficiency is not likely to influence positive selection or negative
selection.
4.2.4 SR-BI deficiency does not impair γδ T cell development
Most T cells are αβ T cells because they express αβ TCR chains. In
contrast, a small group of T cells possess a distinct TCR, namely γδ TCR, and
thus are called γδ T cells, which also develop in the thymus [7]. We investigated
if SR-BI deficiency results in a defect in the development of γδ T cells associated
with thymic hypocellularity. As shown in Figure 4.4, we found that the γδ TCR
expression in DN cells is comparable in SR-BI+/+ and SR-BI-/- thymi,
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demonstrating that SR-BI deficiency does not influence γδ T cell development in
the thymus.
4.2.5 SR-BI deficiency does not influence single positive thymocyte maturation
process
We next evaluated if SR-BI plays a role in SP thymocyte maturation. To
this purpose, we distinguished immature and mature SP thymocytes by the
expression of CD69 and CD62L. In either 4SP (Figure 4.5A and 4.5B) or 8SP
(Figure 4.5C and 4.5D) thymocytes, SR-BI-/- mice do not show significant
changes in the percentage of immature (CD69+CD62Llo) and mature (CD69CD62Lhi) subtypes compared with SR-BI+/+ counterparts, indicating that SR-BI
does not affect in SP thymocyte maturation process.
4.2.6 SR-BI deficiency causes reduced apoptosis of DN thymocytes
We also evaluated if SR-BI deficiency influences thymocyte apoptosis as
elevated thymocyte apoptosis is able to induce thymic hypocellularity in mice. For
this purpose, we detected the DNA strand breaks in thymocytes by TUNEL
analysis. As shown in Figure 4.6A, SR-BI-/- mice display slightly lower rather than
higher TUNEL+ percentage in total thymocytes than SR-BI+/+ mice (Figure 4.6A),
formally excluding the possibility that SR-BI deficiency impairs thymopoiesis by
inducing elevated thymocyte apoptosis. TUNEL analysis in thymocyte subtypes
revealed that the decreased apoptotic cell accumulation in SR-BI-/- thymocytes is
mainly found in the DN population, since the TUNEL+ percentage in DN cells is
25% lower in SR-BI-/- mice than in SR-BI+/+ mice (Figure 4.6A and 4.6B). In
contrast, the TUNEL+ percentages in DP, 4SP and 8SP population are
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comparable between SR-BI+/+ and SR-BI-/- mice. These data indicate that SR-BI
deficiency causes decreased apoptosis in DN thymocytes.
4.2.7 SR-BI deficiency results in decreased proliferation of DN2 thymocytes
SR-BI deficiency could also possibly cause reduced thymus size by
decreasing thymocyte proliferation. To test this possibility, we injected mice with
BrdU and evaluated thymocyte proliferation by measuring BrdU incorporation. As
shown in Figure 4.7A, SR-BI-/- mice do not show significant decline in BrdU+
percentage in thymocytes, indicating that SR-BI deficiency does not cause
thymic hypocellularity by reducing thymocyte proliferation. Interestingly, by
detecting the proliferation of thymocyte subsets, we found that SR-BI-/- mice
exhibit a significantly reduced BrdU+ portion in DN2 thymocytes compared with
SR-BI+/+ controls. In DN3 thymocytes, SR-BI-/- mice also show a strong
decreasing trend in proliferation, though statistical significance is not reached. In
contrast, for DN1 cells, DN4 cells (Figure 4.7A), DP cells, 4SP cells and 8SP
cells (Figure 4.7B), the BrdU+ percentage is not altered by the absence of SR-BI.
These data indicate that SR-BI deficiency results in a decrease in the
proliferation of DN2 and DN3 thymocytes.
4.2.8 SR-BI deficiency decreases the percentage of ETPs
The decreased apoptosis of DN thymocytes and the reduced proliferation
of DN2 and DN3 thymocytes may be linked because β selection occurs in the
DN2 and DN3 stages when cells that fail to express functional TCR-β are
removed by apoptosis. Given that the percentages of thymocyte populations
before and after β selection are not changed in SR-BI-null mice, we speculated
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that fewer DN2 cells are generated to enter β selection in SR-BI-null mice, which
results in the reduction in the proliferation of early DN subsets. DN2 thymocytes
are direct descendants of ETPs, which are a small subset of DN1 cells. Thus,
next we evaluated if SR-BI deficiency affects ETPs in mice. The gating strategy
for ETPs is shown in Figure 4.8A. The mature thymocytes were first excluded by
a panel of lineage markers (anti-CD3ε, CD8α, CD8β, B220, CD19, CD11b,
CD11c, GR-1, NK1.1, Ter119, TCR-β and TCR-γ/δ) and then the ETP was gated
as the CD25-CD44+cKithi population in the Lin- cells [279]. Although SR-BI-/- thymi
exhibit comparable Lin- and Lin-CD25- fractions with SR-BI+/+ controls, their ETP
percentage in Lin-CD25- population and in all thymocytes is reduced by 50% and
40%, respectively (Figure 4.8A and B), together with a 65% decrease in the
number of ETPs (Figure 4.8C). These results clearly indicate that SR-BI
deficiency-induced thymic hypocellularity is accompanied by a decrease in the
portion of ETPs.
4.2.9 SR-BI deficiency does not impair thymopoiesis through affecting lymphoid
progenitor development in bone marrow
As SR-BI deficiency leads to dramatically reduced portion of ETPs, the
most primitive population in thymocytes, we hypothesized that SR-BI deficiency
affects T cell development upstream of ETPs. To test this hypothesis, at first we
evaluated bone marrow lymphoid progenitor development in mice. The gating
strategy of bone marrow lymphoid progenitors is shown in Figure 4.9A. Briefly, a
group of lineage markers (anti-CD2, CD3ε, CD4, CD8α, B220, CD19, CD11b,
GR-1, NK1.1 and Ter119) were first used to exclude mature cells. LSK cells were
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then distinguished as the Sca-1+cKit+ population in Lin- cells and Sca-1intcKitint
population (f1) was meanwhile gated. HSCs, MPPs and LMPPs were gated in
the LSK population based on the expression of CD135 [280]. CLPs were defined
as IL7R+ population in f1 population [281]. In 5-week-old SR-BI-/- mice, we did not
detect any significant difference in either percentages or numbers of gated bone
marrow progenitors compared with SR-BI+/+ mice (Figure 4.9A-4.9C), indicating
that SR-BI deficiency does not affect lymphoid progenitor development in bone
marrow.
4.2.10 SR-BI deficiency causes decreased progenitor homing to the thymus
We next evaluated if SR-BI deficiency impairs bone marrow progenitor
thymic homing. To this purpose, we injected 20 million CFSE-labeled SR-BI+/+
bone marrow cells into non-irradiated SR-BI+/+ and SR-BI-/- mice, and examined
the seeding of labeled bone marrow cells within the thymus two days later. In this
short-term progenitor homing assay, though comparable concentrations of
CFSE+ cells were found in the blood of SR-BI-/- and SR-BI+/+ mice two days after
injection (Figure 4.10A), 34% fewer labeled bone marrow cells were detected in
the thymi of SR-BI-/- mice (Figure 4.10B). These observations reveal that
absence of SR-BI impairs the entry of bone marrow progenitors into the thymus.
4.2.11 SR-BI deficiency leads to a reduced contribution of circulating
progenitors to thymopoiesis
To determine how the reduced bone marrow progenitor entry into the
thymus in SR-BI-/- mice contributes to the downstream T cell development, we
conducted the long-term homing assay, in which 20 million CD45.1+ bone
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marrow cells were injected into non-irradiated mice and thymocyte subtypes
derived from injected CD45.1+ bone marrow cells were analyzed two weeks later.
As expected, the percentage and number of CD45.1 + thymocytes are both
significantly lower in the deficient mice than control mice (Figure 4.11A-C),
indicating that the contribution of circulating bone marrow progenitors to
thymopoiesis is impaired by SR-BI deficiency. Interestingly, despite the reduced
numbers, the CD45.1+ cells in SR-BI-/- thymi show a similar CD4/CD8 profile with
those in SR-BI+/+ mice (Figure 4.11D-E), indicating the downstream development
of settled progenitors is intact in the deficient mice. The numbers of CD45.1+
thymocyte subtypes are all significantly reduced in SR-BI-/- mice (Figure 4.11F).
These findings indicate that SR-BI deficiency impairs thymopoiesis by affecting
the thymic homing process of bone marrow progenitors.
4.2.12 SR-BI deficiency impairs thymic recovery after sublethal irradiation
Because the ETPs and progenitor thymic homing are essential for thymic
regeneration [68, 277], we proposed that SR-BI deficiency results in impaired
thymic recovery after thymocyte depletion. Indeed, using CLP, a model inducing
sepsis and thymocyte depletion in mice [282], we had observed that SR-BI-/- mice
show much smaller thymi and lower thymic cellularity than SR-BI+/+ mice 7 days
after the surgery, which implies that SR-BI deficiency leads to delayed thymic
regeneration (unpublished data). However, CLP is not a good model for studying
the role of SR-BI in thymic recovery because it has been shown that CLP
induces dramatic thymocyte apoptosis in SR-BI+/+ mice but not in SR-BI-/- mice 18
hours after surgery [247], suggesting that SR-BI deficiency may also affect CLP-
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induced thymocyte apoptosis. To induce the same levels of thymocyte depletion
in SR-BI+/+ and SR-BI-/- mice, we utilized the sublethal irradiation model, which is
widely used for investigating thymic recovery [111, 256, 257].
Four days after irradiation, SR-BI+/+ and SR-BI-/- mice show equally low
levels of thymocyte numbers (Figure 4.12A), indicating that in contrast to CLPinduced thymocyte apoptosis, SR-BI deficiency does not affect irradiationinduced thymocyte apoptosis. From day 4 to day 7 post irradiation, thymic
cellularity of SR-BI+/+ mice is increased by 8.4-fold while that of SR-BI-/- mice is
only elevated by 3.1-fold (Figure 4.12A), indicating that the thymic recovery after
irradiation is impaired in the deficient mice. At day 14 after irradiation, the
thymocyte counts of SR-BI-/- mice are still 32% lower than those of SR-BI+/+
controls (Figure 4.12A). We also analyzed the thymic CD4/CD8 profile at day 7
after irradiation. Consistent with former observations in SR-BI-/- mice and in longterm homing assay, we found that 7 days post irradiation, SR-BI-/- mice show a
comparable CD4/CD8 profile with SR-BI+/+ mice (Figure 4.12B), demonstrating
that during thymic recovery, the T cell development is normal inside SR-BI-/thymi. Similarly, the number of DN, DP, 4SP and 8SP thymocytes were all
significantly decreased associated with total thymocyte counts in the deficient
mice (Figure 4.12C). Altogether, these data indicate that SR-BI deficiency
impairs thymic recovery after sublethal irradiation.
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4.3 Summary
In this chapter, we investigated different steps of T cell development to
understand which step of thymopoiesis is modulated by SR-BI. First, we
examined thymocyte subsets in 5-week-old mice and found that SR-BI deficiency
does not cause any obvious blockage in intrathymic T cell development, as
shown by normal percentages of thymocyte subsets (Figure 4.1, 4.2, 4.4 and 4.5)
and unaltered TCR-β expression in all thymocyte subsets (Figure 4.3) in SR-BInull mice. Furthermore, we did not observe increased apoptosis (Figure 4.6) or
decreased proliferation (Figure 4.7) of thymocytes in SR-BI-deficient mice,
excluding the possibility that SR-BI deficiency causes thymic hypocellularity via
affecting thymocyte apoptosis or proliferation. Interestingly, we observed a
remarkable decrease in the portion of ETP in SR-BI-/- thymi (Figure 4.8),
suggesting that SR-BI deficiency impairs thymopoiesis by affecting progenitor
entry into thymus.
We then studied bone marrow progenitor development and thymic homing,
two key steps upstream of ETPs in T cell development in mice. By flow cytometry
analysis of the bone marrow lymphoid progenitors in mice, we found SR-BI
deficiency does not cause any blockage in lymphoid progenitor development
(Figure 4.9). Interestingly, by injecting labeled bone marrow cells into the
circulation of mice, we observed that 2 days later fewer bone marrow cells
homing to the thymus in SR-BI-/- mice (Figure 4.10), demonstrating that SR-BI
deficiency impairs bone marrow progenitor thymic homing. The reduction of bone
marrow progenitor settlement further results in decreased number of downstream
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thymocytes, as shown by that 2 weeks after the labeled bone marrow cell
injection, SR-BI-/- mice show 60% fewer thymocytes derived from labeled bone
marrow cells (Figure 4.11). These data reveal that SR-BI deficiency impairs bone
marrow progenitor thymic homing, which results in the defects in thymopoiesis.
Finally, we investigated if SR-BI deficiency has any effect on thymic
regeneration utilizing the sublethal irradiation model. We found that although the
thymic cellularity of SR-BI+/+ and SR-BI-/- mice is decreased into an equally low
level 4 days after irradiation, the thymocyte numbers of SR-BI-/- mice are 63%
lower than those of SR-BI+/+ mice 7 days after irradiation (Figure 4.12), indicating
that SR-BI is also required for normal thymic regeneration.
Taken together, our results indicate that SR-BI deficiency impairs
thymopoiesis by impairing bone marrow progenitor thymic homing and SR-BI is
required for rapid thymic regeneration after thymocyte depletion.
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Figure 4.1 SR-BI deficiency does not affect the CD4/CD8 profile in mice.
A)-B) Thymocytes from 5-week-old mice were stained with anti-CD4 and antiCD8 to distinguish double negative (DN, CD4-CD8-), double positive (DP,
CD4+CD8+), CD4 single positive (4SP, CD4+CD8-) and CD8 single positive (4SP,
CD4-CD8+) populations. C) The number of each population was calculated by
multiplying its percentage in viable thymocytes by the number of viable
thymocytes. n=5-6 per group.
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Figure 4.2 SR-BI deficiency does not affect the DN1-4 profile in mice.
Thymocytes from 5-week-old SR-BI+/+ or SR-BI-/- mice were stained with a panel
of fluorescence-labeled antibody. A)-B) The DN population was divided into four
subtypes (DN1, CD25-CD44high; DN2, CD25+CD44high; DN3, CD25+CD44low, and
DN4, CD25-CD44low) according to the expression of CD44 and CD25. C) The
number of each population was calculated by multiplying its percentage in DN
thymocytes by the total number of DN thymocytes. n=5-6 per group. *p<0.05.
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Figure 4.3 SR-BI deficiency does not impair selections during
thymopoiesis.
Thymocytes from 5-week-old SR-BI+/+ or SR-BI-/- mice were stained with a panel
of fluorescence-labeled antibody. A) The TCR-β expression was evaluated in DN
population. B)-C) The postselection population in DP cells was defined as CD69 +
TCR-β+ cells. D)-E) The TCR-β expression was evaluated in 4SP and 8SP
population. Representative gating figures are shown. n=3 per group.
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Figure 4.4 SR-BI deficiency does not affect γδ T cell development.
Thymocytes from 5-week-old SR-BI+/+ or SR-BI-/- mice were stained with a panel
of fluorescence-labeled antibody. The TCR-γ/δ expression was evaluated in DN
population. Representative gating plots are shown. n=3 per group.
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Figure 4.5 SR-BI deficiency does not affect γδ T cell development.
The maturation process of 4SP (A and B) or 8SP (C and D) thymocytes from 5week-old mice was evaluated by CD69 and CD62L expression. The immature
population was defined as CD62LloCD69+ SP cells. The mature population was
defined as CD62LhiCD69- SP cells. n=5-6 per group.

102

Figure 4.6 SR-BI deficiency causes reduced apoptosis in DN thymocytes.
Thymocytes from 5-week-old SR-BI+/+ or SR-BI-/- mice were first stained with a
panel of fluorescence-labeled antibody. Cells were then fixed and permeabilized,
before the DNA strand breaks were detected by TUNEL assay. A) The TUNEL+
percentage in all thymocytes and four thymocyte subtypes was statistically
analyzed. B) Representative TUNEL+ gating plots in DN population are
displayed. n=5 per group. *p<0.05.
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Figure 4.7 SR-BI deficiency causes reduced proliferation in DN2
thymocytes.
Thymocytes isolated from 5-week-old SR-BI+/+ or SR-BI-/- mice were first stained
with a panel of fluorescence-labeled antibody before the BrdU incorporation in
thymocytes was detected with the specific antibody. A) BrdU+ percentages in DN
thymocytes and four DN thymocyte subtypes were statistically analyzed. B)
BrdU+ percentage in DP, 4SP and 8SP was statistically analyzed. n=5-7 per
group. *p<0.05.
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Figure 4.8 SR-BI deficiency decreases the portion of ETPs in thymocytes.
Thymocytes isolated from 5-week-old SR-BI+/+ or SR-BI-/- mice were stained with
a panel of fluorescence-labeled antibodies. A) Gating strategy to distinguish
ETPs. The mature thymocytes were first excluded by a panel of lineage markers
(anti-CD3ε, CD8α, CD8β, B220, CD19, CD11b, CD11c, GR-1, NK1.1, Ter119,
TCR-β and TCR-γ/δ) and then the ETP was defined as the CD25-CD44+cKithi
population in Lin- cells. B) Percentage of ETPs in all thymocytes was statistically
analyzed. C) The number of ETPs was calculated by multiplying the percentage
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of ETPs in all thymocytes by the number of total thymocytes. n=5-6 per
group.*p<0.05, **p<0.01.
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Figure 4.9 SR-BI deficiency does not cause defects in lymphoid progenitor
development in bone marrow.
Bone marrow cells from 5-week-old SR-BI+/+ or SR-BI+/+ mice were stained with a
panel of fluorescence-labeled antibodies. A) Gating strategy of bone marrow
lymphoid progenitors. Lineage markers to exclude mature bone marrow cells
include anti-CD2, CD3ε, CD4, CD8α, B220, CD19, CD11b, GR-1, NK1.1 and
Ter119. The HSCs, MPPs and LMPPs were distinguished in LSK population (LinSca-1+cKit+) based on the expression of CD135, and the CLPs were defined as
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IL-7Rα+ population in Lin-Sca-1intcKitint cells. B) The percentages of bone marrow
progenitor populations were analyzed. C) The number of a given progenitor
population was calculated by multiplying its percentage in all bone marrow cells
by total bone marrow cell counts. n=5 per group.
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Figure 4.10 SR-BI deficiency causes reduced progenitor cell settlement on
thymus.
Twenty million CFSE-labeled bone marrow cells from SR-BI+/+ mice were injected
into 5-week-old SR-BI+/+ or SR-BI-/- mice. Two days later, the CFSE+ cells in
blood and thymus were analyzed. SR-BI+/+ mice without bone marrow cell
injection were used as negative controls. A) The percentage of CFSE + cells in
blood cells was shown as the number of CFSE+ cells per 20,000 CD45+ blood
cells. B) The percentage of CFSE+ cells in thymus was shown as the number of
CFSE+ cells per 2 million thymocytes. n=7-8 for CFSE+ cell injected groups; n=2
for no injection group. *, p<0.05.
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Figure 4.11 SR-BI deficiency reduces the contribution of circulating bone
marrow progenitors to thymopoiesis.
Twenty million bone marrow cells from CD45.1 mice were injected into SR-BI+/+
or SR-BI-/- mice in C57BL/6J background. Two weeks later, the contribution of
CD45.1+ bone marrow cells to thymopoiesis was evaluated. A)-B) The
percentage of CD45.1+ cells in thymi was analyzed. C) The number of CD45.1+
population was calculated by multiplying its percentage in thymocytes by total
thymocyte numbers. D)-E) The CD4/CD8 profile was analyzed in CD45+ cells. E)
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The number of a given population in CD45+ cells was calculated by multiplying its
percentage in CD45.1+ cells by the number of CD45.1+ cells. n=5-6 per group.
*p<0.05; **p<0.01.
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Figure 4.12 SR-BI deficiency impairs thymic recovery after sublethal
irradiation.
SR-BI+/+ and SR-BI-/- mice were irradiated with a single dose of 450 rads from a
cesium source. Thymocytes were analyzed at indicated times after the
irradiation. A) Thymocyte numbers of mice were analyzed at indicated times
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after irradiation. n=3-5 per group. B) The thymocyte CD4/CD8 profiles were
analyzed 7 days after irradiation. C) The number of a given population was
calculated by multiplying its percentage in thymocytes by the number of total
thymocytes. n=4-5 per group. **p<0.01, ***p<0.001.
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Chapter 5

Adrenal SR-BI is required for maintaining normal thymopoiesis

and thymic regeneration
5.1 Introduction
SR-BI is a multifunctional receptor expressed in a variety of tissues. SR-BI
expressed in different tissues can exert various functions in a number of
physiological or pathological processes [135, 159]. For instance, hepatic SR-BI
mediates selective uptake from HDL and acts as the key modulator of HDL
metabolism [202, 209], adrenal SR-BI controls steroid production under stress
[160, 206], and macrophage SR-BI facilitates cholesterol efflux [283] and
suppresses inflammatory responses [192]. In chapter 4 we revealed which step
of thymopoiesis is affected by SR-BI deficiency. We found that in the absence of
SR-BI, mice display impaired progenitor thymic homing, which is responsible for
the decreased thymopoiesis. However, how SR-BI deficiency causes these
defects in T cell development has not been clear. Therefore, in this chapter, we
utilized different mouse models to investigate how the impairments of
thymopoiesis are induced by the deficiency of SR-BI.
Given that SR-BI is expressed in T-lineage cells as well as other
hematopoietic cells [134], the first question we asked was that how the lack of
hematopoietic or non-hematopoietic SR-BI contributes to the thymus defects in
SR-BI-null mice. Actually, the progenitor homing assays (Figure 4.10 and Figure
4.11) suggested that the non-hematopoietic SR-BI deficiency is at least partly
responsible for the impaired thymopoiesis, as we injected the same labeled cells
into SR-BI+/+ or SR-BI-/- environment and detected fewer cells homing to the
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thymi of SR-BI-/- mice. To determine whether hematopoietic SR-BI deficiency
contributes to the impaired thymopoiesis and confirm the contribution of nonhematopoietic SR-BI deficiency, we utilized a series of bone marrow
transplantation models. Our data indicate that lacking SR-BI in hematopoietic
cells does not lead to any defects in thymopoiesis whereas the nonhematopoietic SR-BI deficiency is responsible for the impaired thymopoiesis in
SR-BI-null mice.
The observation that the impaired thymopoiesis of SR-BI-null mice is due
to non-hematopoietic SR-BI deficiency raised the possibility that the
thymopoiesis defects are induced by the SR-BI deficiency-induced
hypercholesterolemia. Indeed, several detects due to SR-BI deficiency have
been linked to the hypercholesterolemia [135], such as abnormal erythropoiesis
[212, 213], female infertility [210], and impaired lymphocyte homeostasis [134].
Therefore, we hypothesized that non-SR-BI deficiency impairs thymopoiesis by
causing hypercholesterolemia. To test this hypothesis, we manipulated plasma
cholesterol levels in mice. We found that neither exacerbating nor normalizing
hypercholesterolemia affects thymic cellularity of SR-BI-null mice, indicating the
impaired thymopoiesis is not due to SR-BI deficiency-induced
hypercholesterolemia.
One study reported that cholesterol accumulation in thymic macrophages
activates NLRP3 inflammasome, which contributes to the age-related thymic
involution in mice [65]. This report led us to hypothesize that SR-BI deficiency
impairs thymopoiesis by causing cholesterol accumulation in thymic
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macrophages and subsequent NLRP3 activation in mice. However, we did not
observe cholesterol accumulation in thymic macrophages of SR-BI-null mice, nor
did we detect NLRP3 inflammasome activation, demonstrating that SR-BI
deficiency does not cause thymus defects via inducing cholesterol accumulation
in thymic macrophages.
Our findings excluded the involvement of the altered cholesterol
metabolism in the impaired thymopoiesis of SR-BI-null mice, which led us to
consider alternative explanations of how SR-BI deficiency leads to the defects in
thymopoiesis. In addition to hypercholesterolemia, another well-studied defect in
SR-BI-null mice is the impaired adrenal function. SR-BI-mediated cholesterol
uptake is an essential pathway to supply cholesterol to adrenal glands for steroid
synthesis [161]. Lack of SR-BI in adrenal causes a deficiency of inducible
steroids [206-208], which is responsible for the elevated septic death [206] and
the lack of thymocyte apoptosis during sepsis[247]. We utilized adrenal
transplantation models to evaluate if the defects in thymopoiesis were a result of
the adrenal SR-BI deficiency. Surprisingly, we found that mice with a loss of
adrenal SR-BI in mice display defects in T cell development similar with SR-BInull mice, demonstrating that loss of SR-BI in adrenal gland is the responsible for
the impaired thymopoiesis.
In this chapter, we provide data indicating that the adrenal SR-BI is
required for maintaining normal T cell development in mice, whereas neither SRBI deficiency-induced hypercholesterolemia nor a lack of hematopoietic SR-BI is
responsible for the impaired thymopoiesis in SR-BI-null mice.
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5.2 Results
5.2.1 Hematopoietic SR-BI deficiency does not influence thymopoiesis
To investigate whether hematopoietic SR-BI deficiency contributes to the
impaired thymopoiesis, we compared the ability of SR-BI-/- bone marrow cells in
competing with CD45.1+ bone marrow cells in thymopoiesis with that of SR-BI+/+
bone marrow cells in lethally irradiated Rag-1-/- recipients (Figure 5.1A). Notably,
the SR-BI-/- mice and their SR-BI+/+ littermates used in this assay were all
backcrossed more than 10 times to the C57BL/6J background. Rag-1-/- mice
were chosen as recipients because they lack T-lineage cells beyond DN3 stage
[284] and therefore we can exclude the influence of recipient-derived T-lineage
cells on the process of thymocyte repopulation. Six weeks after bone marrow
transplantation, Rag-1-/- mice transplanted with SR-BI-/- and SR-BI+/+ bone
marrow cell mixes show similar CD45.2+ percentage in total thymocytes (Figure
5.1B and 5.1C). Meanwhile, the CD45.2+ percentage in DN, DP, 4SP and 8SP
subsets is all comparable in two groups, indicating that SR-BI-/- bone marrow
cells have intact ability to support thymopoiesis. These results reveal that the
impaired thymopoiesis in SR-BI-/- mice is not attributed to the hematopoietic SRBI deficiency.
5.2.2 Non-hematopoietic SR-BI deficiency is responsible for impaired
thymopoiesis
We next investigated the contribution of non-hematopoietic SR-BI
deficiency to the impaired thymopoiesis. For this purpose, we repopulated
lethally irradiated SR-BI-/-Rag-1-/- mice and SR-BI+/+Rag-1-/- controls with CD45.1+
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bone marrow cells (Figure 5.2A). Unexpectedly, before detecting thymopoiesis
endpoints six weeks after bone marrow transplantation, we observed a
significantly higher mortality in SR-BI-/-Rag-1-/- after bone marrow transplantation
(Figure 5.2B). Though all the SR-BI+/+Rag-1-/- recipients survived after the
transplantation, all the male and one in four female SR-BI-/-Rag-1-/- recipients
died (Figure 5.2C), indicating non-hematopoietic SR-BI deficiency indeed causes
a survival disadvantage in bone marrow transplantation.
We then evaluated the development of CD45.1+ cells in the thymi of
survived recipients 6 weeks after BMT. In both groups of recipients, over 85%
thymocytes are CD45.1+ cells (Figure 5.3A), indicating the successful thymic
repopulation with donor cells. However, SR-BI-/-Rag-1-/- recipients display 30%
lower CD45.1+ thymocytes numbers than SR-BI+/+Rag-1-/- recipients (Figure
5.3B). Analysis of CD4/CD8 profile in CD45.1+ cells reveals that SR-BI-/- Rag-1-/recipients do not show significant differences in the percentage of CD45.1+
thymocyte subtypes (Figure 5.3C), while only the number of CD45.1+ DP cells
are significantly reduced in SR-BI-/-Rag-1-/- recipients (Figure 5.3D). Interestingly,
the donor-derived ETPs are also significantly reduced both in percentage and
numbers in SR-BI-/- Rag-1-/- recipients (Figure 5.3E and F). This group of data
shows that non-hematopoietic SR-BI deficiency impairs the ability of bone
marrow cells to repopulate thymi and thus is responsible for the impaired
thymopoiesis in SR-BI-/- mice.
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5.2.3 Non-hematopoietic SR-BI deficiency causes decreased T cell pool in the
periphery
We also evaluated whether non-hematopoietic SR-BI deficiency affects
peripheral T cell repopulation after bone marrow transplantation. Consistent with
the observations in the thymus, we found that in lymph nodes of SR-BI-/-Rag-1-/recipients, the numbers of donor-derived CD4+ and CD8+ cells are reduced by
34% and 44%, respectively, compared with those of SR-BI+/+Rag-1-/- recipients
(Figure 5.4A). Moreover, SR-BI-/- Rag-1-/- recipients show significantly reduced
donor-derived CD4+ cells in spleen (Figure 5.4B), and markedly decreased
donor-derived CD4+ and CD8+ cells in blood (Figure 5.4C). These findings
indicate that non-hematopoietic SR-BI deficiency impairs not only the
regeneration of the thymus but also the repopulation of peripheral T cells after
bone marrow transplantation.
5.2.4 Diet-induced hypercholesterolemia does not influence thymic cellularity or
ETPs
SR-BI deficiency in mice causes hypercholesterolemia, which further
leads to other several defects in mice (discussed in chapter 1.2), we asked if
hypercholesterolemia is also responsible for defective thymopoiesis in SR-BI-/mice. At first, we detected the plasma cholesterol in 5-week-old mice and
confirmed that at 5 weeks of age, SR-BI deficiency results in a more than twofold elevation in plasma cholesterol concentrations (Figure 5.5A). To determine if
general hypercholesterolemia has an effect on thymic cellularity in early ages, we
fed C57BL/6N mice with high fat diet starting from the age of 3 weeks and
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analyzed thymopoiesis two weeks later. As expected, high fat diet-fed C57BL/6N
mice display a 4-fold increase in cholesterol concentrations (Figure 5.5B), which
notably is even higher than in SR-BI-/- mice. However, compared with mice on
control diet, high fat diet-fed mice do not show any difference in thymic cellularity
(Figure 5.5C). Meanwhile, the percentages (Figure 5.5D) and numbers of ETPs
(Figure 5.5E) are also comparable in high fat diet-fed mice and controls. These
data demonstrate that diet-induced hypercholesterolemia does not result in
thymic hypocellularity or reduction in ETPs.
5.2.5 SR-BI deficiency-induced hypercholesterolemia is not responsible for
impaired thymopoiesis
Because SR-BI deficiency-induced hypercholesterolemia is different from
diet-induced hypercholesterolemia as it is characterized by increases in HDL
cholesterol [114, 156], we next determined whether or not the
hypercholesterolemia due to SR-BI deficiency causes the thymic abnormalities
seen in SR-BI-/- mice. For this purpose, we fed SR-BI-/- mice with high fat diet
from the age of 3 weeks until analyzing their thymi at the age of 5 weeks. High fat
diet exaggerates hypercholesterolemia in SR-BI-/- mice by 3-fold (Figure 5.6A)
and slightly decreases their thymocyte numbers (Figure 5.6B). However,
compared with control-diet SR-BI-/- mice, high-fat-diet SR-BI-/- mice do not show
reductions in either the percentage or the number of ETPs (Figure 5.6C and
5.6D), suggesting the exacerbated thymic cellularity is not due to further
decreased ETPs. Given that the high fat diet contains cholic acid that accelerates
cholesterol absorption [285, 286] but can cause inflammation [287], we reasoned
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that the further decrease in thymocyte number of high fat diet-fed SR-BI-/- mice
may result from inflammation-induced thymocyte depletion. To exclude the side
effect of the diet and clarify the effect of elevated cholesterol concentration in SRBI-/- mice on thymus, we compared thymocyte numbers in SR-BI-/- mice with agematched SR-BI-/-LDLR-/- mice, whose cholesterol concentrations are elevated
endogenously compared with SR-BI-/- mice [182]. We found that the thymic
cellularity is not lower in 5-week-old or 20-week-old SR-BI-/-LDLR-/- mice than in
age-matched SR-BI-/- mice (Figure 5.6E), demonstrating that the exaggerated
hypercholesterolemia does not exacerbate thymic hypocellularity in the SR-BIdeficient animal.
In addition to increasing hypercholesterolemia in SR-BI-/- mice, we also
corrected hypercholesterolemia in SR-BI-/- mice by probucol administration and
evaluated its effect on thymus. We started to administer 0.2% probucol to SR-BI-/mice at 3 weeks of age. Two weeks later, the plasma cholesterol concentration of
the deficient mice is normalized to levels similar to those in SR-BI+/+ mice (Figure
5.7A). However, the thymocyte number of SR-BI-/- mice with probucol
administration is not elevated compared to mice without this treatment (Figure
5.7B), indicating that the thymic hypocellularity is not caused by elevated
cholesterol levels. To exclude the possibility that the relieved
hypercholesterolemia for two weeks is insufficient to influence the thymic
cellularity in SR-BI-/- mice, we maintained the deficient mice on the probucol diet
for as long as 15 weeks. Similarly, we observed comparable thymic cellularity in
SR-BI-/- mice with or without probucol administration (Figure 5.7C). Altogether,
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these data indicate that SR-BI deficiency-induced hypercholesterolemia is not the
leading cause for impaired thymopoiesis.
5.2.6 SR-BI deficiency does not cause thymic hypocellularity through activating
NLRP3 inflammasome
Recently it was reported that age-dependent accumulation of danger
signals such as free cholesterol in thymic macrophages induces activation of the
NLRP3 inflammasome which contributes to age-related thymic involution [65].
Given the essential role of SR-BI in cholesterol transport, we hypothesized that
SR-BI deficiency impairs thymopoiesis by causing increased cholesterol
accumulation in thymic macrophages and subsequent activation of the NLRP3
inflammasome at younger ages. To test this hypothesis, we first evaluated
cholesterol levels in thymic macrophages (F4/80+CD11b+ thymocytes) of 5-weekold mice by filipin staining. We found that 5-week-old SR-BI-/- mice do not exhibit
elevated cholesterol levels in thymic macrophages in comparison with SR-BI+/+
mice (Figure 5.8A and 5.8B), indicating SR-BI deficiency does not cause
cholesterol accumulation in thymic macrophages of young mice. To fully rule out
the involvement of NLRP3 inflammasome in SR-BI deficiency-impaired
thymopoiesis, we evaluated NLPR3 inflammasome activation in the thymi of mice
by detecting the cleavage of caspase 1, a hallmark of NLPR3 inflammasome
activation [288, 289]. Similarly, we did not detect p20, the cleaved subunits of
caspase 1, in either SR-BI+/+ or SR-BI-/- mice at the age of 5 weeks or 6 months
(Figure 5.8C). These observations indicate that SR-BI deficiency does not impair
thymopoiesis via NLRP3 inflammasome activation in mice.
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5.2.7 Adrenal SR-BI deficiency reduces thymus size
To determine if adrenal SR-BI plays a role in modulating thymopoiesis, we
transplanted adrenal gland from SR-BI+/+ or SR-BI-/- mice to adrenalectomized
SR-BI+/+ mice. Six weeks after surgery, the recipient mice receiving SR-BI-/adrenal gland (ADR-T SR-BI-/- mice) display significantly reduced thymus weight
than those receiving SR-BI+/+ one (ADR-T SR-BI+/+ mice), indicating that the loss
of SR-BI in adrenal gland is responsible for the reduction in thymus weight
(Figure 5.9A). Moreover, the thymic cellularity of ADR-T SR-BI-/- mice is ~40%
lower than that of ADR-T SR-BI+/+ mice, indicating that the absence of adrenal
SR-BI leads to thymic hypocellularity (Figure 5.9B). These results reveal that
adrenal SR-BI is essential in maintaining normal thymus size.
5.2.8 Adrenal SR-BI deficiency does not affect CD4/CD8 profile or DN1-4 profile
in the thymus
We next investigated thymocyte subsets of the adrenal transplanted mice.
Similar to SR-BI-/- mice, ADR-T SR-BI-/- mice displayed identical CD4/CD8 profile
(Figure 5.10A) and DN1-4 profile (Figure 5.10C) with the ADR-T SR-BI+/+ controls.
The numbers of DN, DP, 4SP, 8SP (Figure 5.10B) and the DN subtypes (Figure
5.10D) in ADR-T SR-BI-/- were all reduced corresponding with the total thymocyte
counts. These observations indicate that the loss of SR-BI in adrenal does not
affect thymic CD4/CD8 profile or DN1-4 profile.
5.2.9 Adrenal SR-BI deficiency reduces the percentage of ETPs
We also evaluated if adrenal SR-BI deficiency leads to a reduction in the
percentage of ETPs. Compared with ADR-T SR-BI+/+ controls, ADR-T SR-BI-/-
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mice exhibit a 30% decrease in the percentage of ETPs (Figure 5.11A) and a 65%
decrease in their numbers (Figure 5.11B), which again mimics the phenotype of
SR-BI-/- mice. These data indicate that the adrenal SR-BI deficiency is
responsible for the reduction in the percentage of ETPs in SR-BI-null mice.
5.2.10 Adrenal SR-BI deficiency causes impaired thymic recovery after
sublethal irradiation
Finally, we sublethally irradiated the adrenal transplanted mice in order to
assess if adrenal SR-BI deficiency results in delayed thymic regeneration. Seven
days after irradiation, ADR-T SR-BI-/- mice exhibit smaller thymus weight (Figure
5.12A) and 48% lower thymic cellularity (Figure 5.12B) than ADR-T SR-BI+/+ mice,
indicating the thymic recovery is delayed by adrenal SR-BI deficiency. In line with
the observations in SR-BI-/- mice, the percentages of DN, DP, 4SP and 8SP
thymocytes in ADR-T SR-BI-/- mice are not significantly different in ADR-T SRBI+/+ mice (Figure 5.12C). The numbers of all these populations in ADR-T SR-BI-/mice (Figure 5.12D) are all reduced compared with ADR-T SR-BI+/+ mice after
the irradiation. These results reveal that adrenal SR-BI is required for normal
thymic regeneration.
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5.3 Summary
In this chapter, we investigated how the SR-BI deficiency causes defects
in T cell development. First, using bone marrow transplantation models, we show
that hematopoietic SR-BI deficiency does not cause any defect in thymopoiesis
as SR-BI-/- bone marrow cells display a comparable ability to give rise to
thymocytes with SR-BI+/+ controls (Figure 5.1); and non-hematopoietic SR-BI
deficiency results in impaired thymopoiesis as in SR-BI-/- recipients, bone marrow
cells display reduced ability to support thymopoiesis compared with in SR-BI+/+
recipients (Figure 5.3 and 5.4). Next, using cholesterol-manipulating models, we
show that non-hematopoietic SR-BI deficiency does not impair thymopoiesis
through inducing hypercholesterolemia. In SR-BI+/+ mice, diet-induced
thymopoiesis fails to induce thymus defects (Figure 5.5); and in SR-BI-/- mice,
neither exaggerating nor normalizing hypercholesterolemia alters thymocyte
numbers (Figure 5.6 and 5.7). By detecting cholesterol in thymic macrophages
and evaluating NLRP3 inflammasome activation in the thymus, we excluded the
possibility that non-hematopoietic SR-BI deficiency causes thymus defects by
inducing cholesterol accumulation in thymic macrophages in young mice (Figure
5.8). Finally, using adrenal transplantation models, we show that SR-BI
deficiency in adrenal gland is responsible for the thymus defects in SR-BI-null
mice, since mice with adrenal-specific SR-BI deficiency display reduced thymus
size (Figure 5.9), decreased ETP percentage (Figure 5.11) and delayed thymic
regeneration (Figure 5.12). Based on these findings, we conclude that adrenal
SR-BI is critical in thymopoiesis and thymic recovery in mice.
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Figure 5.1 Hematopoietic SR-BI deficiency does not cause any defect in
thymopoiesis.
A) Design for the bone marrow cell competition experiments. CD45.1+ bone
marrow cells were mixed with either SR-BI+/+ bone marrow cells or SR-BI-/- bone
marrow cells (both CD45.2+) with a ratio of 1:1. Five million mixed bone marrow
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cells were then injected into lethally irradiated Rag-1-/- mice. Six weeks later, the
development of CD45.1+ and CD45.2+ (either SR-BI+/+ or SR-BI-/-) cells in the
thymi of recipients were evaluated. All the SR-BI+/+ and SR-BI-/- mice used as
donors in this experiments were in C57BL/6J background. B) Representative
CD45.1+ and CD45.2+ gating plots in total thymocytes are displayed. C) The
CD45.2+ percentage in all thymocytes and four thymocyte subtypes was
statistically analyzed. n=5-6 per group.
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Figure 5.2 Non-hematopoietic SR-BI deficiency increases the death rate in
bone marrow transplantation.
A) Design for the bone marrow transplantation experiment. Five million CD45.1+
bone marrow cells were injected into lethally irradiated SR-BI+/+Rag-1-/- or SR-BI/-

Rag-1-/- mice. B) Survival curve of SR-BI+/+Rag-1-/- or SR-BI-/-Rag-1-/- mice after

bone marrow transplantation is shown. C) The survival rate of SR-BI+/+Rag-1-/- or
SR-BI-/-Rag-1-/- mice by gender after bone marrow transplantation is displayed.
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Figure 5.3 Non-hematopoietic SR-BI deficiency is responsible for impaired
thymopoiesis.
Five million CD45.1+ bone marrow cells were injected into lethally irradiated SRBI+/+Rag-1-/- or SR-BI-/-Rag-1-/- mice. Six weeks later, the development of
CD45.1+ cells in the thymi of recipients were evaluated. A) The percentage of
CD45.1+ cells in all thymocytes was analyzed. B) The number of CD45.1 + cells
was calculated by multiplying the percentage of CD45.1+ cells in all thymocytes
by the number of total thymocytes. C) The CD4/CD8 profile was analyzed in
CD45.1+ cells. D) The number of a given population in CD45+ cells was
calculated by multiplying its percentage in CD45.1+ cells by the number of
CD45.1+ cells. E) The ETP percentage was analyzed in CD45+ cells. F) The
number of ETPs in CD45+ cells was calculated by multiplying its percentage in
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CD45.1+ cells by the number of CD45.1+ cells. n=3-9 per group. *, p<0.05; **,
p<0.01; ***, p<0.001.
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Figure 5.4 Non-hematopoietic SR-BI deficiency impairs peripheral
lymphocyte repopulation after bone marrow transplantation.
Five million CD45.1+ bone marrow cells were injected into lethally irradiated SRBI+/+Rag-1-/- or SR-BI-/-Rag-1-/- mice. Six weeks later, CD45.1+ T cell numbers in
the lymph nodes (A), spleen (B) or blood (C) were evaluated. The number of a
given population was calculated by multiplying the its percentage in CD45.1 +
cells in lymph nodes, spleen or blood by the CD45.1 + cell numbers in lymph
nodes or spleen, or the CD45.1+ cell concentration in blood. n=3-9 per group. *,
p<0.05; ***, p<0.001.
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Figure 5.5 Diet-induced hypercholesterolemia does not affect
thymopoiesis.
A) Plasma cholesterol concentrations were determined in 5-week-old SR-BI+/+
and SR-BI-/- mice. n= 3 per group. B)-E) C57BL/6N mice were fed with high fat
diet or control diet starting from the age of 3 weeks. Two weeks later, plasma
cholesterol concentrations (B), thymocyte numbers (C), the percentage (D) and
numbers (E) of ETP were analyzed. n=5 per group. **, p<0.01; ***p<0.001.
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Figure 5.6 Elevating hypercholesterolemia in SR-BI-deficient mice does
not further impair thymopoiesis.
A)-D) SR-BI-/- mice were fed with high fat diet or control diet starting from the age
of 3 weeks. Two weeks later, plasma cholesterol concentrations (A), thymocyte
numbers (B), the percentage (C) and numbers (D) of ETPs were analyzed. n= 45 per group. E) Thymocyte numbers of 5-week-old or 20-week-old SR-BI-/- or SRBI-/-LDL-/- mice were analyzed. n=2-4 per group for 5-week-old group; n=9-12 per
group for 20-week-old group. ***, p<0.001.
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Figure 5.7 Relieving hypercholesterolemia in SR-BI-deficient mice does
not correct thymic hypocellularity.
SR-BI-/- mice were fed with a diet containing 0.2% probucol or control diet starting
from the age of 3 weeks. A)-B) Two weeks later, plasma cholesterol
concentrations (A) and thymocyte numbers (B) were analyzed. n=5-7 per group.
C) Fifteen weeks later, thymocyte numbers were analyzed. n=7-9 per group. **,
p<0.01.
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Figure 5.8 SR-BI deficiency does not impair thymopoiesis through
activating NLRP3 inflammasome.
A)-B) Thymocytes of 5-week-old SR-BI+/+ and SR-BI-/- mice were stained with
surface markers and then fixed/ permeabilized, before staining with filipin. A) The
thymic macrophage was defined as the F4/80+CD11b+ population in thymocytes
and the filipin staining in gated thymic macrophage is shown. B) The mean
fluorescence density (MFI) of filipin in thymic macrophages was statistically
analyzed. n=3 per group. C) Thymi from SR-BI+/+ and SR-BI-/- mice were lysed
and the whole-thymus lysates were subject to western blot analysis with anticaspase-1 (4B4) and anti-β-tublin. Representative results from two experiments
were showed.
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Figure 5.9 Adrenal SR-BI deficiency reduces thymic size.
SR-BI+/+ mice (10-12 weeks) were adrenalectomized and transplanted with
adrenal gland from either SR-BI+/+ or SR-BI-/- donors (9 days) under the right
kidney capsule. Six weeks later, thymus weight (A) and thymic cellularity (B)
were analyzed. n=4-5 per group. **, p<0.01; ***, p<0.001.
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Figure 5.10 Adrenal SR-BI deficiency does not change thymic CD4/CD8
profile or DN1-4 profile.
SR-BI+/+ mice (10-12 weeks) were adrenalectomized and transplanted with one
adrenal gland from either SR-BI+/+ or SR-BI-/- donors (9 days) under the right
kidney capsule. Six weeks later, thymocyte subsets of the recipient mice were
evaluated. A) The CD4/CD8 profile was analyzed. B) The number of a given
population was calculated by multiplying its percentage in thymocytes by the total
number of thymocytes. C) The DN1-4 profile was analyzed. D) The number of a
given DN population was calculated by multiplying its percentage in DN
thymocytes by the number of DN thymocytes. n=4-5 per group. *, p<0.05; **,
p<0.01; ***, p<0.001.
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Figure 5.11 Adrenal SR-BI deficiency decreases the portion of ETPs.
SR-BI+/+ mice (10-12 weeks) were adrenalectomized and transplanted with one
adrenal gland from either SR-BI+/+ or SR-BI-/- donors (9 days) under the right
kidney capsule. Six weeks later, thymocyte subsets of the recipient mice were
evaluated. A) The percentage of ETPs was analyzed. B) The number of ETP
was calculated by multiplying its percentage in thymocytes by the total number of
thymocytes. n=4-5 per group. *, p<0.05; **, p<0.01.
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Figure 5.12 Adrenal SR-BI deficiency delays thymic recovery after
sublethal irradiation.
SR-BI+/+ mice (10-12 weeks) were adrenalectomized and transplanted with one
adrenal gland from either SR-BI+/+ or SR-BI-/- donors (9 days) under the right
kidney capsule. Six weeks later, recipient mice were irradiated with a single dose
of 450 rads from a cesium source. Seven days after irradiation, the mice were
sacrificed. A) Thymus weight was analyzed. B) Thymocyte numbers of mice
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were analyzed. C) The thymocyte CD4/CD8 profile was analyzed. D) The
number of a given population was calculated by multiplying its percentage in
thymocytes by the number of total thymocytes. n=7-9 per group. *, p<0.05.
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Chapter 6

Discussion

6.1 Summary of this project
In this project, we identified SR-BI, a well-established HDL receptor that
can bind a wide range of ligands, as a novel player in thymopoiesis. Loss of SRBI in mice leads to a significant reduction in thymus weight (Figure 3.1) and
thymic hypocellularity (Figure 3.2) after puberty, which is associated with a
marked decrease in T cell production (Figure 3.5). Meanwhile, SR-BI deficiency
also induces delayed thymic recovery after sublethal irradiation (Figure 4.12).
These findings indicate that SR-BI is required for normal thymopoiesis and
thymic regeneration.
In the process of T cell development, SR-BI deficiency impairs the thymic
homing process of bone marrow progenitors (Figure 4.10 and 4.11), causing
reduced progenitor entry in the thymus and a decreased percentage of ETPs
(Figure 4.8). In contrast, SR-BI deficiency does not influence the lymphoid
progenitor development in bone marrow (Figure 4.9). T cell developmental
processes downstream of ETP are also normal in SR-BI-null mice, as their
percentages of thymocyte subsets (Figure 4.1, 4.2 and 4.5) and the expression
of TCR-β in thymocytes (Figure 4.3) are all unaltered. In addition, the reduced
thymus size of SR-BI-null mice is not due to an increase in thymocyte apoptosis
or a decrease in thymocyte proliferation, as we only detected minor changes in
apoptosis (Figure 4.6) and proliferation (Figure 4.7) of DN thymocytes, which
may be linked to the decrease of ETPs.
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Consistent with the reduction in T cell production, SR-BI deficiency leads
to a narrowed naïve T cell pool. The naïve CD4+ and naïve CD8+ cell numbers
are all decreased in lymph nodes (Figure 3.6 and Figure 3.7), spleen (Figure 3.8)
and blood (Figure 3.9) of SR-BI-/- mice at young ages. An increase in proliferation
of naïve T cells was also detected in the deficient mice (Figure 3.9). These
observations indicate that the reduced T cell production due to SR-BI deficiency
impairs T cell homeostasis in the periphery. Moreover, T cells isolated from SRBI-null mice display reduced responses to TCR stimuli (Figure 3.10 and 3.11),
suggesting that the reduction in T cell production also compromises T cell
function in these mice.
Using bone marrow transplantation models, we show that the absence of
SR-BI in hematopoietic cells does not cause any defect in T cell development
whereas the non-hematopoietic SR-BI deficiency is responsible for those defects.
The hypercholesterolemia in SR-BI-null mice is not likely the leading cause for
the defects in thymus, as neither exaggerating hypercholesterolemia in SR-BInull mice further decreases their thymic cellularity (Figure 5.6), nor does
normalizing hypercholesterolemia relieve their thymic hypocellularity (Figure 5.7).
In addition, young SR-BI-null mice do not exhibit cholesterol accumulation in
thymic macrophages or activation of NLRP3 inflammasome in the thymus (Figure
5.8), indicating that thymic hypocellularity is not related to thymic macrophage
cholesterol accumulation-induced NLRP3 inflammasome activation.
Unexpectedly, we observed that the loss of SR-BI in adrenal gland leads to
decreased thymus size, reduced ETP percentage and delayed thymic recovery
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(Figure 5.9-5.12). With these findings, we demonstrate that the impaired
thymopoiesis in SR-BI-null mice is attributed to the adrenal SR-BI deficiency.
6.2 T cell development in the absence of SR-BI
From the HSCs in bone marrow to the mature naïve T cells in the
periphery, T cell development can be divided to two major components, lymphoid
progenitor development in the bone marrow and the T cell development in the
thymus. These two major processes are connected by progenitor thymic homing,
in which LMPPs and CLPs migrate from bone marrow to enter thymus via the
circulation and then participate in thymopoiesis. Because thymus lacks selfrenewal progenitors, long term T cell production requires continuous progenitor
entry into thymus [68].
In the absence of SR-BI, the progenitor thymic homing processes in mice
are impaired, leading to reduced thymus size and decreased thymic cellularity.
The impaired progenitor thymic homing due to SR-BI deficiency is directly
elucidated with progenitor homing assays. In these assays, we show that when
comparable concentrations of bone marrow cells are present in the circulation,
fewer bone marrow cells settle into thymi in SR-BI-/- mice than in SR-BI+/+ mice
(Figure 4.10). Moreover, the reduced amount of seeded progenitors gives rise to
fewer downstream thymocytes in the deficient mice, indicating that the
contribution of circulating bone marrow progenitors to generating developing
thymocyte is also impaired (Figure 4.11). Meanwhile, in the bone marrow
transplantation models, the decreased repopulation of donor-derived thymocytes
(Figure 5.3) and reduced numbers of donor-derived peripheral T cells (Figure
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5.4) in SR-BI-/-Rag-1-/- recipients can also be explained by the impaired
progenitor homing, as they are transplanted with the same numbers of donor
bone marrow cells via the circulation with SR-BI+/+Rag-1-/- recipients. These three
models together reveal the fact that due to the impaired thymic homing, fewer
bone marrow progenitors enter thymus in the absence of SR-BI, which leads to
the thymic hypocellularity and the reduced T cell generation.
A direct consequence of the impaired thymic homing is a decrease in the
percentage of ETPs. For example, CCR7/CCR9 double knockout mice and Pselectin glycoprotein ligand 1 (PSGL-1) knockout mice, in whom the progenitor
thymic homing is blocked, display significant reduction in the percentage of ETPs
in thymocytes [83, 84]. SR-BI-null mice also show a dramatic reduction in the
percentage of ETPs (Figure 4.8). In addition, SR-BI-null mice exhibit unchanged
percentage of DN1-4 profile (Figure 4.2) and reduced thymic cellularity (Figure
3.2), which is similar to the other two mouse strains whose progenitor thymic
homing is reduced [83, 84]. Interestingly, we detected a significant decrease in
the proliferation of DN2 population in SR-BI-null mice (Figure 4.7). Because DN2
cells are direct descendants of ETPs, the reduced proliferation is probably due to
the reductions in ETPs. The decreased apoptosis of DN cells (Figure 4.6) may be
a consequence of the reduced proliferation of DN2 cells, which we speculate
causes fewer DN cells to enter β-selection.
The other steps of T cell development in SR-BI-null mice appear normal.
For the lymphoid progenitor development in bone marrow, we did not observe
any change in the percentage or the number of bone marrow progenitors in SR-
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BI-null mice, indicating there is not any significant blockage in the lymphoid
progenitor development. The thymopoiesis events downstream of ETPs are also
intact in SR-BI-null mice. First, SR-BI-null mice display normal a CD4/CD8 profile
(Figure 4.1) and DN1-4 profile (Figure 4.2), indicating that there is not a
significant blockage between thymocyte subtypes. Second, SR-BI-null mice
exhibit identical TCR-β expression in thymocytes (Figure 4.3), indicating that the
selection processes are not altered by SR-BI deficiency. Third, SR-BI-null mice
display unchanged percentage of immature and mature SP cells (Figure 4.5),
indicating intact SP cell maturation in these mice. Finally, SR-BI-null mice do not
show reduced proliferation or elevated apoptosis in most thymocyte subtypes,
excluding the possibility that SR-BI deficiency impairs thymopoiesis by
decelerating the proliferation or increasing apoptosis of thymocytes. More
importantly, in the long-term homing assay, although fewer numbers of donorderived thymocytes were detected in SR-BI-/- mice, the CD4/CD8 profile of donorderived thymocytes is identical in SR-BI-/- mice and SR-BI+/+ controls (Figure
4.11). This observation indicates that the settled progenitors in SR-BI-null thymi,
despite lower numbers, are following a normal developmental program to
generate downstream thymocytes, strongly supporting that SR-BI deficiency
does not affect T cell development downstream of ETPs. In addition, in bone
marrow transplanted SR-BI-/- mice (Figure 5.3) and sublethal irradiated SR-BI-/mice (Figure 4.12), the CD4/CD8 profiles of thymocytes are also not significantly
changed, further indicating the intact T cell development downstream of ETPs.
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The impairment in progenitor thymic homing and the reduction of ETPs in
SR-BI-null mice lead to reduced thymus size, which is characterized by the
decrease in thymus weight (Figure 3.1) and the thymic hypocellularity (Figure
3.2). Notably, the reduction in thymus size was not observed in 1-week-old SRBI-null mice (Figure 3.4), indicating SR-BI does not impair thymus development
before birth.
6.3 SR-BI deficiency-impaired thymopoiesis contributes to the lymphocyte
imbalance
Our data reveal that the T cell production is decreased by the SR-BI
deficiency, since both the frequency and the number of TRECs, which are
correlated with RTEs, are reduced in the T cells of SR-BI-null mice (Figure 3.5).
As a consequence of the reduction in T cell production, young SR-BI-null mice
display impaired T cell homeostasis in the periphery, characterized by reduced
naïve T cell portion (Figure 3.6-3.8) and increased naïve T cell (Figure 3.9)
proliferation.
Interestingly, 5-week-old and 20-week-old SR-BI-null mice display marked
differences in lymphocytes. Formerly, our group reported that 20-week-old SR-BI/-

mice have T cell expansion and hyperactivation in spleen. Though the reduced

naïve T cell percentage was also observed in 20-week-old SR-BI-/- mice, we
thought it was due to the heightened T cell activation, because their naïve T cell
numbers are not decreased, whereas the memory T cell numbers are
significantly increased [134]. Results from current project show that the reduced
thymopoiesis actually has a contribution to the decrease in the portion of naïve T
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cells. Five-week-old SR-BI-null mice exhibit a remarkable reduction in naïve T
cell pool in lymph nodes, spleen and blood. Nevertheless, memory T cells are not
increased in any of these sites (Figure 3.6 and 3.6), indicating that at young age,
SR-BI deficiency does not induce T cell hyperactivation, but the reduction in
thymopoiesis has started to affect the T cell homeostasis. The number of T cells
is not higher in 5-week-old SR-BI-null mice than wild-type mice (Figure 3.6E),
indicating that T cell expansion also has not been induced by SR-BI deficiency in
5-week-old mice. The T cell homeostasis in lymph nodes of 13-week-old SR-BInull mice is similar with 5-week-old SR-BI-null mice (Figure 3.7), but the T cells in
spleen have shown a slight expansion (data not shown), indicating that between
5 weeks and 20 weeks of age, the dysfunctional HDL begins to take over,
increasing T cell numbers and inducing the T cell hyperactivation.
Consistent with former reports showing that the reduced T cell production
causes compromised T cell functions [62-64], we found that T cells from SR-BInull mice display impaired responsiveness to stimuli (Figure 3.10 and 3.11). We
speculate the impaired T cell function in SR-BI-null mice is linked with the
reduced refreshment of T cell pool by RTEs, which is known to be responsible for
increased longevity of naïve T cells and accumulation of anergic T cells [54].
However, as dysfunctional HDL from SR-BI-null mice can also modulate T cells,
we cannot exclude its contribution to the impaired T cell functions. Further
investigation is warranted to further understand how the reduction in T cell
function is induced by SR-BI deficiency.
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We also reported that aged SR-BI-null mice suffer from an autoimmune
problem, as shown by increased autoantibody concentration in the circulation,
and elevated lymphocyte infiltration and the presence of immunocomplexes in
the kidney [134]. The lymphocyte hyperactivation due to the dysfunctional HDL in
SR-BI-null mice was thought to be the leading cause of the autoimmune
problems. Our current findings raise the possibility that the autoimmune disease
due to SR-BI deficiency is influenced by the impaired thymopoiesis, as
thymopoiesis can remove the self-reactive T cells in the periphery [54] and
reduced T cell production is known to cause autoimmune problems [57]. The
underlying mechanisms by which SR-BI deficiency leads to the autoimmune
problem will be an interesting subject for future study.
6.4 Impaired thymopoiesis in SR-BI-null mice is not due to hematopoietic SR-BI
deficiency or abnormal cholesterol metabolism
In addition to investigating how T cell development is changed in SR-BInull mice, we studied how SR-BI deficiency causes these changes. Because SRBI is expressed in hematopoietic cells such as T cells, B cells [134], and
macrophages [290], it is possible that absence of SR-BI in hematopoietic cells is
responsible for the T cell development defects. Hematopoietic SR-BI deficiency
has been shown to induce elevated susceptibility to atherosclerosis [178, 182,
188-190], increased inflammation [192], and the red blood cell abnormalities
(unpublished data). However, Our data indicate that hematopoietic SR-BI
deficiency is not responsible for the thymic defects, as bone marrow cells from
SR-BI-null mice do not show any disadvantage in supporting thymopoiesis
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compared with those from wild-type mice in bone marrow transplantation
experiments (Figure 5.1).
If hematopoietic SR-BI deficiency does not lead to impaired thymopoiesis,
it follows that non-hematopoietic SR-BI deficiency causes the thymic defects in
SR-BI-null mice. Using another group of bone marrow transplantation assay, we
confirmed the contribution of non-hematopoietic SR-BI deficiency to the thymic
defects. SR-BI-deficient recipients display reduced donor-derived cells in the
thymus (Figure 5.3) and decreased peripheral donor-derived T cells (Figure 5.4),
indicating that the non-hematopoietic SR-BI deficiency environment is the major
cause of impaired thymopoiesis. Moreover, in the progenitor homing assays,
labeled bone marrow cells show lower ability to settle in the thymus (Figure 4.10)
and give rise to downstream thymocytes in SR-BI-/- recipients (Figure 4.11),
further suggesting that the non-hematopoietic SR-BI deficiency causes impaired
progenitor thymic homing in mice.
The fact that the non-hematopoietic SR-BI deficiency causes impaired
thymopoiesis led us to ask if the impaired thymopoiesis is induced by the SR-BI
deficiency-induced hypercholesterolemia. Actually, several defects due to SR-BI
deficiency has been shown to be secondary to the defective cholesterol
metabolism [135]. For example, SR-BI deficiency causes erythrocyte defects
through inducing cholesterol accumulation in erythrocyte [212, 213]; and SR-BI
deficiency-induced female infertility is caused by the abnormal HDL particles
[210]. Abnormalities that are caused by defective cholesterol metabolism in SRBI-deficient mice can be relieved by normalizing the cholesterol metabolism. For
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instance, treatment with probucol, a cholesterol lowering drug, in SR-BI-/- mice is
able to correct some defects, including increased susceptibility to cardiovascular
disease [262], female infertility [210], and abnormalities in red blood cells [262].
More importantly, the lymphocyte expansion and hyperactivation is correlated
with the level of hypercholesterolemia in mice, as in SR-BI-null mice, lymphocyte
expansion is exaggerated by elevated hypercholesterolemia; and furthermore it
can be corrected by normalization of hypercholesterolemia (unpublished data).
However, we did not obtain the same results with T cell development in SR-BInull mice. We found that neither elevating hypercholesterolemia nor correcting
hypercholesterolemia in SR-BI-null mice has any effect on their thymic cellularity
(Figure 5.6 and 5.7), indicating the impaired T cell development is apparently not
likely linked with impaired cholesterol metabolism.
Our findings are not inconsistent with current knowledge on how
cholesterol metabolism is linked with T cell development. It was reported that
deficiency of ABCG1, a key transporter mediating cholesterol efflux in RCT [244,
245], causes increased cholesterol accumulation in thymocytes, which induces
increased thymocyte proliferation [241]. We find that SR-BI-null mice do not show
increased cholesterol accumulation in thymocytes (data not shown) or elevated
proliferation rate, indicating SR-BI is not an essential player in regulating
cholesterol homeostasis in thymocytes. Also it was reported that free cholesterol
accumulation in thymic macrophages induces activation of NLRP3
inflammasome, which contributes to age-related thymic involution [65]. We
observed that young SR-BI-null mice do not have cholesterol accumulation in
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thymic macrophages, nor do they show the activation of NLRP3 inflammasome
in thymus (Figure 5.8), indicating that SR-BI deficiency also does not affect
cholesterol homeostasis in thymic macrophages.
Taken together, our data indicate that the impaired thymopoiesis in SR-BInull mice is caused by the non-hematopoietic SR-BI deficiency but it is not due to
the impaired cholesterol homeostasis. SR-BI deficiency should cause the defects
in T cell development via an alternative mechanism.
6.5 Adrenal SR-BI deficiency is responsible for impaired thymopoiesis
To figure out the mechanism by which SR-BI deficiency leads to the
impaired thymopoiesis, we evaluated the contribution of adrenal SR-BI deficiency
to the impaired thymopoiesis. SR-BI expressed in adrenal gland is essential in
mediating the uptake of cholesterol from HDL, which provides cholesterol as
resources for steroid synthesis [161]. Using adrenal transplantation models,
Hoekstra M et al. showed that the absence of SR-BI in adrenal gland causes
glucocorticoid insufficiency during fasting, highlighting the essential role of
adrenal SR-BI in vivo [171]. The glucocorticoid insufficiency in SR-BI-null mice
has been shown to be responsible for elevated inflammation, decreased
thymocyte apoptosis and increased death rate in sepsis [135, 206, 247].
In this study, we also utilized adrenal transplantation technique to
generate mice with SR-BI deficiency in adrenal gland. We found that the ADR-T
SR-BI-/- mice display identical thymic phenotypes with SR-BI-/- mice. Compared
with ADR-T SR-BI+/+ mice, ADR-T SR-BI-/- mice show significantly reduced
thymus weight and thymic cellularity (Figure 5.9), unaltered CD4/CD8 profile
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(Figure 5.10) and decreased portion of ETPs (Figure 5.11). Notably, it was six
weeks after adrenal transplantation that we observed changes in the thymus.
Given that all the thymocytes can be fully replaced by bone marrow progenitorderived cells in four weeks [54], at the time point we evaluated the thymi, the
thymocytes of the adrenal transplanted mice should all be originated from bone
marrow cells that enter thymi after surgery. Thus, the thymic defects in ADR-T
SR-BI-/- mice are likely due to the impaired thymic homing. These findings
indicate that the impaired thymopoiesis of SR-BI-null mice is induced by its
abnormal adrenal functions.
These results are surprising for two major reasons. First, although adrenal
SR-BI deficiency causes impaired adrenal functions, previous data indicated that
it only causes an insufficiency of inducible glucocorticoid. Under normal
conditions, the adrenal function is considered normal, as no significant decrease
in the concentration of circulating glucocorticoid was detected in SR-BI-null mice
[206, 207]. However, the impaired thymopoiesis is seen in young SR-BI-null mice
under normal conditions. The linkage between the SR-BI deficiency in adrenal
gland and the impaired thymopoiesis indicates that the adrenal functions of SRBI-null mice are not intact as was thought previously. Absence of adrenal SR-BI
leads to changes in adrenal steroid production under normal conditions, which
subsequently causes the defects in T cell development. How adrenal function is
affected by SR-BI deficiency under normal condtions warrant further study.
Second, our findings appear contradictory to current concepts on the
effect of steroids on thymopoiesis. Prior to our study, the effect of glucocorticoid
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on T cell development has been intensively investigated. It is well known that
during inflammatory process such as sepsis, a high level of glucocorticoid is
induced that causes thymocyte apoptosis [291, 292]. Under normal conditions,
glucocorticoid is also predicted to suppress T cell development as evidenced by
the findings that overexpression of GC receptor in thymocytes leads to
decreased thymic cellularity in mice [293] and adrenalectomy is well-known to
cause an increase in thymocyte numbers [294, 295]. The discovery of the
intrathymic glucocorticoid synthesis [296-298] indicated the effect of
glucocorticoid is more complicated than originally thought. The intrathymic
glucocorticoid seems to be regulated differently from its adrenal production [299],
and it has been shown to play a role in regulating thymus size [293, 299] and
selection processes in thymopoiesis [300, 301]. Given that adrenal SR-BI causes
impaired adrenal function and reduced inducible glucocorticoid production, one
may predict that adrenal deficiency of SR-BI should contribute to increasing
thymus size. But interestingly we got an opposite observation.
How impaired adrenal function causes impaired thymopoiesis is a puzzle
that remains to be solved. However, for the first time, we demonstrate that the
progenitor homing process is the link between them. It is worth noting that SR-BI
controls the synthesis of not only glucocorticoids but also several other steroids
[135]. The decrease in the production of other steroids may be responsible for
the impaired thymopoiesis in the adrenal SR-BI-deficient mice, as the
physiological concentrations of glucocorticoids are not changed. Further
investigation is warranted to identify how the adrenal SR-BI deficiency changes T
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cell development, which may lead to novel findings on the roles of steroids in
thymopoiesis.
6.6 SR-BI is required for normal thymic regeneration
Another major finding in this project is that SR-BI deficiency causes
impaired thymic regeneration. Using the sublethal irradiation model, which
mimics the whole body irradiation in humans, we found that SR-BI-null mice
show a slower recovery after the thymocyte depletion (Figure 4.12). The
irradiation causes thymocyte depletion and reduces thymocytes of SR-BI+/+ and
SR-BI-/- mice to comparably low levels in 4 days. After the lowest point,
thymocytes are increased by 8.4-fold in SR-BI+/+ mice 7 days after irradiation. In
contrast, in SR-BI-/- mice these cells are only elevated by 3.1-fold. As long as 14
days after irradiation, the thymocyte numbers of SR-BI-/- mice are still 40% lower
than that of SR-BI+/+ mice, clearly indicating impaired thymic recovery after
irradiation. Similarly, during the recovery from CLP-induced sepsis, the
thymocyte numbers of SR-BI-null mice are also much smaller than those of wildtype controls 7 days after the surgery (data not shown), which probably also
results from the delayed thymic recovery due to SR-BI deficiency.
Both the irradiation resistant T cell progenitors such as ETP and the
circulating bone marrow progenitors have been shown to be essential for the
thymic recovery [68, 277]. In the sublethal irradiation model, the thymic recovery
is mainly dependent on the intrathymic T cell progenitors, as it usually takes
around 2 weeks for circulating progenitors to develop to double positive stage [77,
277]. In our long term homing assay, two weeks after the injection of bone

154

marrow cells into the non-irradiated mice, the donor-derived cells are only ~1% in
total thymocytes (Figure 4.11A and B), also indicating a slow contribution of
circulating bone marrow cells to thymopoiesis. Thus, in the sublethally irradiated
SR-BI-null mice, the delayed thymic recovery is mainly attributed to the decrease
in the percentage of ETPs. Actually, our bone marrow transplantation
experiments in which we tested the contribution of non-hematopoietic SR-BI
deficient to the impaired thymopoiesis (Figure 5.3), can be seen as a model to
evaluate the contribution of circulating progenitors to thymic recovery in SR-BInull mice. In this model, most intrathymic progenitors are deleted by lethal
irradiation and thus the thymic regeneration is mainly dependent on circulating
progenitors [277]. The reduced donor-derived thymocyte numbers and ETPs in
SR-BI-/-Rag-1-/- recipients after bone marrow transplantation indicate that the
impaired thymic homing is also responsible for the compromised thymic recovery
in SR-BI-null mice.
More importantly, we show that adrenal SR-BI deficiency induces the
impaired thymic recovery after sublethal irradiation (Figure 5.12), providing a
formerly unseen link between adrenal function and thymic regeneration. As
thymocyte depletion increases the risks to infection and is extremely slow to
recover [109, 110, 113], understanding how adrenal function plays a role in
regulating thymic regeneration may lead to novel methods to accelerate thymic
recovery in patients.
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6.7 Prospective
In this project, we discovered that adrenal SR-BI is required to maintain
normal thymopoiesis and T cell homeostasis. Several key questions still remain
to be solved. The most important of these is how SR-BI deficiency impairs
adrenal function under normal conditions and how impaired adrenal function
induces the defects in T cell development. Answering this question could be
challenging, because SR-BI controls synthesis of multiple steroids in adrenal,
and each steroid (such as glucocorticoids) may play complex roles in T cell
development. However, understanding how the adrenal-generated steroid affects
thymopoiesis will be of great significance, as it may lead to new strategies to
increase thymic functions in the elderly or patients with thymocyte depletion.
Another interesting question will be how progenitor thymic homing is
affected by adrenal SR-BI deficiency. The thymic homing process is mediated by
several adhesion molecules. It is possible the adhesion molecules on thymic
endothelial cells or bone marrow progenitors are down-regulated in SR-BI-null
mice. Or, SR-BI deficiency may cause more bone marrow progenitor cell death in
the circulating. Elucidating how SR-BI deficiency affects thymic homing will
deepen our understanding of the regulation of progenitor thymic homing, a
process that has not been well-understood.
In addition, many detailed questions regarding the adaptive immune
system of SR-BI-null mice remain to be solved. For example, how the impaired
thymopoiesis and dysfunctional HDL-induced T cell expansion contribute to the
impaired lymphocyte homeostasis and the autoimmune problem; how the TCR
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repertories and the primary immune responses are affected by SR-BI deficiency;
and how SR-BI deficiency affects the non T-lineage cells in thymus.
Understanding the role of SR-BI in immunity may generate novel findings that
link HDL metabolism or adrenal functions to the immune system.
In summary, in this project, we identified a formerly unseen function of SRBI in thymopoiesis. SR-BI deficiency causes reduced thymic size, decreased T
cell production and delayed thymic recovery in mice by causing impaired
progenitor thymic homing. Adrenal SR-BI deficiency is responsible for the defects
in T cell development.
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